Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Chronic Heart Failure

  Free Subscription


Articles published in Eur J Heart Fail

Retrieve available abstracts of 503 articles:
HTML format
Text format



Single Articles


    December 2018
  1. NOUGUE H, Pezel T, Picard F, Sadoune M, et al
    Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
    Eur J Heart Fail. 2018 Dec 6. doi: 10.1002/ejhf.1342.
    PubMed     Text format     Abstract available


  2. GROENEWEGEN A, Rutten FH
    Near-home heart failure care.
    Eur J Heart Fail. 2018 Dec 6. doi: 10.1002/ejhf.1345.
    PubMed     Text format    


    November 2018
  3. WAGENAAR KP, Broekhuizen BDL, Jaarsma T, Kok I, et al
    Effectiveness of the European Society of Cardiology/Heart Failure Association website 'heartfailurematters.org' and an e-health adjusted care pathway in patients with stable heart failure: results of the 'e-Vita HF' randomized controlled trial.
    Eur J Heart Fail. 2018 Nov 28. doi: 10.1002/ejhf.1354.
    PubMed     Text format     Abstract available


  4. TSCHOPE C, Kherad B, Klein O, Lipp A, et al
    Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond.
    Eur J Heart Fail. 2018 Nov 28. doi: 10.1002/ejhf.1349.
    PubMed     Text format     Abstract available


  5. ADAMOPOULOS S, Corra U, Laoutaris ID, Pistono M, et al
    Exercise training in patients with ventricular assist devices: a review of the evidence and practical advice. A position paper from the Committee on Exercise Physiology and Training and the Committee of Advanced Heart Failure of the Heart Failure Asso
    Eur J Heart Fail. 2018 Nov 26. doi: 10.1002/ejhf.1352.
    PubMed     Text format     Abstract available


  6. GEVAERT AB, Beckers PJ, Van Craenenbroeck AH, Lemmens K, et al
    Endothelial dysfunction and cellular repair in heart failure with preserved ejection fraction: response to a single maximal exercise bout.
    Eur J Heart Fail. 2018 Nov 23. doi: 10.1002/ejhf.1339.
    PubMed     Text format    


  7. SENNI M, Iorio A, Seferovic P
    Heart failure with preserved ejection fraction in Asia: the far side of the moon?
    Eur J Heart Fail. 2018 Nov 23. doi: 10.1002/ejhf.1335.
    PubMed     Text format    


  8. PARATI G, Ochoa JE
    Prognostic value of baroreflex sensitivity in heart failure. A 2018 reappraisal.
    Eur J Heart Fail. 2018 Nov 23. doi: 10.1002/ejhf.1334.
    PubMed     Text format    


  9. GREENE SJ, Fonarow GC, Solomon SD, Subacius HP, et al
    Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial.
    Eur J Heart Fail. 2018 Nov 11. doi: 10.1002/ejhf.1310.
    PubMed     Text format    


  10. CELUTKIENE J, Plymen CM, Flachskampf FA, de Boer RA, et al
    Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2018 Nov 9. doi: 10.1002/ejhf.1330.
    PubMed     Text format     Abstract available


  11. GREENE SJ, Felker GM, Butler J
    Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care.
    Eur J Heart Fail. 2018 Nov 5. doi: 10.1002/ejhf.1341.
    PubMed     Text format    


  12. METRA M
    November 2018 at a glance: from prediction of heart failure in asymptomatic subjects to advanced chronic heart failure.
    Eur J Heart Fail. 2018;20:1503-1504.
    PubMed     Text format    


    October 2018
  13. SUZUKI T, Yazaki Y, Voors AA, Jones DJL, et al
    Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure (from BIOSTAT-CHF).
    Eur J Heart Fail. 2018 Oct 29. doi: 10.1002/ejhf.1338.
    PubMed     Text format     Abstract available


  14. COWIE MR, Gallagher AM, Simonds AK
    Treating central sleep apnoea in heart failure: is pull better than push?
    Eur J Heart Fail. 2018 Oct 23. doi: 10.1002/ejhf.1337.
    PubMed     Text format    


  15. VAN DER POL A, van Gilst WH, Voors AA, van der Meer P, et al
    Treating oxidative stress in heart failure: past, present and future.
    Eur J Heart Fail. 2018 Oct 19. doi: 10.1002/ejhf.1320.
    PubMed     Text format     Abstract available


  16. FERREIRA JP, Metra M, Mordi I, Gregson J, et al
    Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study.
    Eur J Heart Fail. 2018 Oct 19. doi: 10.1002/ejhf.1323.
    PubMed     Text format     Abstract available


  17. LILJEROOS M, Stromberg A
    Introducing nurse-led heart failure clinics in Swedish primary care settings.
    Eur J Heart Fail. 2018 Oct 19. doi: 10.1002/ejhf.1329.
    PubMed     Text format     Abstract available


  18. WOLLERT KC
    Growth differentiation factor-15 reveals the dark side of heart failure.
    Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1327.
    PubMed     Text format    


  19. SEQUEIRA V, Maack C
    Rebalancing protein phosphorylation in heart failure to prevent arrhythmias.
    Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1315.
    PubMed     Text format    


  20. CIKES M, Sanchez-Martinez S, Claggett B, Duchateau N, et al
    Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy.
    Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1333.
    PubMed     Text format     Abstract available


  21. CAMPBELL RT, Petrie MC, McMurray JJV
    Redefining heart failure phenotypes based on ejection fraction.
    Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1325.
    PubMed     Text format    


  22. PABEL S, Wagner S, Bollenberg H, Bengel P, et al
    Empagliflozin directly improves diastolic function in human heart failure.
    Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1328.
    PubMed     Text format     Abstract available


  23. MCDONAGH T, Damy T, Doehner W, Lam CSP, et al
    Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice.
    Eur J Heart Fail. 2018 Oct 12. doi: 10.1002/ejhf.1305.
    PubMed     Text format     Abstract available


  24. COSTANZO MR, Ponikowski P, Coats A, Javaheri S, et al
    Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure.
    Eur J Heart Fail. 2018 Oct 10. doi: 10.1002/ejhf.1312.
    PubMed     Text format     Abstract available


  25. PATEL HC, Kaye DM
    Exercise training in heart failure: a long way to go yet.
    Eur J Heart Fail. 2018 Oct 9. doi: 10.1002/ejhf.1332.
    PubMed     Text format    


  26. MCCARTHY CP, Vaduganathan M, Pandey A
    Developing evidence-based and accountable health policy in heart failure.
    Eur J Heart Fail. 2018 Oct 8. doi: 10.1002/ejhf.1331.
    PubMed     Text format    


  27. CAMPBELL RT, Petrie MC, McMurray JJV
    Talking to patients with heart failure about end of life.
    Eur J Heart Fail. 2018 Oct 8. doi: 10.1002/ejhf.1321.
    PubMed     Text format    


  28. STRENG KW, Lang CC, Voors AA
    What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure? Reply.
    Eur J Heart Fail. 2018 Oct 8. doi: 10.1002/ejhf.1324.
    PubMed     Text format    


  29. PAPP Z, Radovits T, Paulus WJ, Hamdani N, et al
    Molecular and pathophysiological links between heart failure with preserved ejection fraction and type 2 diabetes mellitus.
    Eur J Heart Fail. 2018 Oct 2. doi: 10.1002/ejhf.1318.
    PubMed     Text format    


  30. CORRA U, Agostoni PG, Anker SD, Coats AJS, et al
    Corrigendum to 'Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology' [Eur
    Eur J Heart Fail. 2018;20:1501.
    PubMed     Text format    


    September 2018
  31. TAYLOR RS, Walker S, Smart NA, Piepoli MF, et al
    Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials.
    Eur J Heart Fail. 2018 Sep 26. doi: 10.1002/ejhf.1311.
    PubMed     Text format     Abstract available


  32. MULLENS W, Verbrugge FH, Nijst P, Martens P, et al
    Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial.
    Eur J Heart Fail. 2018 Sep 21. doi: 10.1002/ejhf.1307.
    PubMed     Text format     Abstract available


  33. KOEHLER F, Koehler K, Deckwart O, Prescher S, et al
    Telemedical Interventional Management in Heart Failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and descrip
    Eur J Heart Fail. 2018 Sep 19. doi: 10.1002/ejhf.1300.
    PubMed     Text format     Abstract available


  34. GREENBERG B, Fang J, Mehra M, Stevenson LW, et al
    Advanced heart failure: Trans-Atlantic perspectives on the Heart Failure Association of the European Society of Cardiology position statement.
    Eur J Heart Fail. 2018 Sep 18. doi: 10.1002/ejhf.1313.
    PubMed     Text format    


  35. VENTURA HO, Carbone S, Lavie CJ
    Muscling up to improve heart failure prognosis.
    Eur J Heart Fail. 2018 Sep 18. doi: 10.1002/ejhf.1314.
    PubMed     Text format    


  36. PACKER M
    The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation, and heart failure with a preserved ejection fraction.
    Eur J Heart Fail. 2018 Sep 17. doi: 10.1002/ejhf.1294.
    PubMed     Text format    


  37. VOORS AA, Shah SJ, Bax JJ, Butler J, et al
    Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.
    Eur J Heart Fail. 2018 Sep 17. doi: 10.1002/ejhf.1295.
    PubMed     Text format     Abstract available


  38. BOUABDALLAOUI N, Claggett B, Zile MR, McMurray JJV, et al
    Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.
    Eur J Heart Fail. 2018 Sep 11. doi: 10.1002/ejhf.1301.
    PubMed     Text format     Abstract available


  39. FISCHER TH, Eiringhaus J, Dybkova N, Saadatmand A, et al
    Activation of protein phosphatase 1 by a selective phosphatase disrupting peptide reduces sarcoplasmic reticulum Ca(2+) leak in human heart failure.
    Eur J Heart Fail. 2018 Sep 7. doi: 10.1002/ejhf.1297.
    PubMed     Text format     Abstract available


  40. PALECZNY B, Olesinska-Mader M, Siennicka A, Niewinski P, et al
    Assessment of baroreflex sensitivity has no prognostic value in contemporary, optimally managed patients with mild-to-moderate heart failure with reduced ejection fraction: a retrospective analysis of 5-year survival.
    Eur J Heart Fail. 2018 Sep 6. doi: 10.1002/ejhf.1306.
    PubMed     Text format     Abstract available


  41. METRA M
    September 2018 at a glance: co-morbidities, heart failure with preserved ejection fraction and mineralocorticoid receptor antagonists.
    Eur J Heart Fail. 2018;20:1245-1246.
    PubMed     Text format    


    August 2018
  42. LUO N, O'Connor CM, Cooper LB, Sun JL, et al
    Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION.
    Eur J Heart Fail. 2018 Aug 31. doi: 10.1002/ejhf.1299.
    PubMed     Text format     Abstract available


  43. EMAMI A, Saitoh M, Valentova M, Sandek A, et al
    Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
    Eur J Heart Fail. 2018 Aug 30. doi: 10.1002/ejhf.1304.
    PubMed     Text format     Abstract available


  44. CAO TH
    What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure?
    Eur J Heart Fail. 2018 Aug 23. doi: 10.1002/ejhf.1303.
    PubMed     Text format    


  45. GODINO C, Scotti A, Munafo A, Taramasso M, et al
    Observed versus predicted mortality after MitraClip treatment in patients with symptomatic heart failure and significant functional mitral regurgitation.
    Eur J Heart Fail. 2018 Aug 23. doi: 10.1002/ejhf.1291.
    PubMed     Text format    


  46. TROMP J, Teng TH, Tay WT, Hung CL, et al
    Heart failure with preserved ejection fraction in Asia.
    Eur J Heart Fail. 2018 Aug 16. doi: 10.1002/ejhf.1227.
    PubMed     Text format     Abstract available


  47. GRAZIANI F, Varone F, Crea F, Richeldi L, et al
    Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis.
    Eur J Heart Fail. 2018 Aug 7. doi: 10.1002/ejhf.1286.
    PubMed     Text format     Abstract available


  48. GAGLIARDI C, Perfetto F, Lorenzini M, Ferlini A, et al
    Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
    Eur J Heart Fail. 2018 Aug 2. doi: 10.1002/ejhf.1285.
    PubMed     Text format     Abstract available


  49. VAN WOERDEN G, Gorter TM, Daan Westenbrink B, Willems TP, et al
    Epicardial fat in heart failure patients with mid-range and preserved ejection fraction.
    Eur J Heart Fail. 2018 Aug 1. doi: 10.1002/ejhf.1283.
    PubMed     Text format     Abstract available


    July 2018
  50. MAGINI A, Farina S, Riggio D, Sandri MT, et al
    ST2 and B-type natriuretic peptide kinetics during exercise in severe heart failure.
    Eur J Heart Fail. 2018 Jul 27. doi: 10.1002/ejhf.1246.
    PubMed     Text format    


  51. COTTER G, Davison BA
    Unmodifiable events, heart failure research, and 'risk-based monitoring' in large studies-the unholy triumvirate.
    Eur J Heart Fail. 2018 Jul 27. doi: 10.1002/ejhf.1282.
    PubMed     Text format    


  52. SCHMITTO JD, Pya Y, Zimpfer D, Krabatsch T, et al
    Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark Study.
    Eur J Heart Fail. 2018 Jul 27. doi: 10.1002/ejhf.1284.
    PubMed     Text format     Abstract available


  53. DOEHNER W, Celutkiene J, Haeusler KG
    Central command in heart failure: was there effect of hemispheric lateralization in insular cortex activation? Reply.
    Eur J Heart Fail. 2018 Jul 13. doi: 10.1002/ejhf.1281.
    PubMed     Text format    


  54. CARBONE S, Elagizi A, Lavie CJ
    Obesity and mortality risk in heart failure: when adipose tissue distribution matters.
    Eur J Heart Fail. 2018 Jul 12. doi: 10.1002/ejhf.1279.
    PubMed     Text format    


  55. MAHMOOD SS, Patel RB, Butler J, Vaduganathan M, et al
    Epirubicin and long-term heart failure risk in breast cancer survivors.
    Eur J Heart Fail. 2018 Jul 4. doi: 10.1002/ejhf.1215.
    PubMed     Text format    


  56. STRENG KW, Voors AA, Hillege HL, Anker SD, et al
    Waist-to-hip ratio and mortality in heart failure.
    Eur J Heart Fail. 2018 Jul 2. doi: 10.1002/ejhf.1244.
    PubMed     Text format     Abstract available


  57. JAARSMA T, van der Wal M, Hjelmfors L, Stromberg A, et al
    Talking about palliative care in heart failure.
    Eur J Heart Fail. 2018 Jul 2. doi: 10.1002/ejhf.1239.
    PubMed     Text format    


  58. PATEL KV, Pandey A
    Prognostic implications of microvascular complications in patients with diabetes and heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2018 Jul 2. doi: 10.1002/ejhf.1253.
    PubMed     Text format    


  59. METRA M
    July 2018 at a glance: practical guidance in acute heart failure, pathophysiology and clinical trials of medical therapy.
    Eur J Heart Fail. 2018;20:1079-1080.
    PubMed     Text format    


    June 2018
  60. CAMPBELL RT, Petrie MC, Jackson CE, Jhund PS, et al
    Which patients with heart failure should receive specialist palliative care?
    Eur J Heart Fail. 2018 Jun 28. doi: 10.1002/ejhf.1240.
    PubMed     Text format     Abstract available


  61. COOPER LB, Yap J, Tay WT, Teng TK, et al
    Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1223.
    PubMed     Text format     Abstract available


  62. ANKER MS, von Haehling S, Landmesser U, Coats AJS, et al
    Cancer and heart failure-more than meets the eye: common risk factors and co-morbidities.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1252.
    PubMed     Text format    


  63. CUTHBERT JJ, Pellicori P, Rigby A, Pan D, et al
    Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1247.
    PubMed     Text format     Abstract available


  64. SIMONOVIC D, Coiro S, Carluccio E, Girerd N, et al
    Exercise elicits dynamic changes in extravascular lung water and haemodynamic congestion in heart failure patients with preserved ejection fraction.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1228.
    PubMed     Text format    


  65. PASCUAL-FIGAL D, Bayes-Genis A
    The misperception of 'stable' heart failure.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1248.
    PubMed     Text format    


  66. PATEL RB, Vaduganathan M, Greene SJ, Butler J, et al
    Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology.
    Eur J Heart Fail. 2018 Jun 26. doi: 10.1002/ejhf.1231.
    PubMed     Text format    


  67. VACCARO O, Riccardi G, Maggioni AP
    Risk of heart failure in diabetic patients receiving sulfonylureas.
    Eur J Heart Fail. 2018 Jun 22. doi: 10.1002/ejhf.1238.
    PubMed     Text format    


  68. AMBROSY AP, Chioncel O
    Combination drug therapy in heart failure: greater than the sum of its parts.
    Eur J Heart Fail. 2018 Jun 22. doi: 10.1002/ejhf.1251.
    PubMed     Text format    


  69. KREMER D, Ter Maaten JM, Voors AA
    Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure.
    Eur J Heart Fail. 2018 Jun 22. doi: 10.1002/ejhf.1245.
    PubMed     Text format    


  70. OBOKATA M, Borlaug BA
    The strengths and limitations of E/e' in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2018 Jun 22. doi: 10.1002/ejhf.1250.
    PubMed     Text format    


  71. IORIO A, Senni M, Barbati G, Greene SJ, et al
    Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study.
    Eur J Heart Fail. 2018 Jun 19. doi: 10.1002/ejhf.1202.
    PubMed     Text format     Abstract available


  72. WOLSK E
    Heart failure and co-morbidity revisited; the elephant in the room.
    Eur J Heart Fail. 2018 Jun 19. doi: 10.1002/ejhf.1225.
    PubMed     Text format    


  73. GRODIN JL, Testani JM, Pandey A, Sambandam K, et al
    Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
    Eur J Heart Fail. 2018 Jun 12. doi: 10.1002/ejhf.1229.
    PubMed     Text format     Abstract available


  74. SOKORELI I, Pauws SC, Riistama JM, Cleland JG, et al
    Psychosocial factors and mortality in patients with heart failure: reply.
    Eur J Heart Fail. 2018 Jun 12. doi: 10.1002/ejhf.1224.
    PubMed     Text format    


  75. NAGAI M, Dote K, Kato M
    Central command in heart failure: was there effect of hemispheric lateralization in insular cortex activation?
    Eur J Heart Fail. 2018 Jun 11. doi: 10.1002/ejhf.1233.
    PubMed     Text format    


  76. PACKER M
    Risk of heart failure in diabetic patients receiving sulfonylureas: reply.
    Eur J Heart Fail. 2018 Jun 11. doi: 10.1002/ejhf.1232.
    PubMed     Text format    


  77. BUTLER J, Vijayakumar S, Pitt B
    Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists.
    Eur J Heart Fail. 2018 Jun 8. doi: 10.1002/ejhf.1217.
    PubMed     Text format    


  78. NAUTA JF, Hummel YM, van der Meer P, Lam CSP, et al
    Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patient
    Eur J Heart Fail. 2018 Jun 7. doi: 10.1002/ejhf.1220.
    PubMed     Text format     Abstract available


  79. METRA M
    June 2018 at a glance: peripartum cardiomyopathy and pathophysiology, prognosis, and device therapy of heart failure.
    Eur J Heart Fail. 2018;20:949-950.
    PubMed     Text format    


    May 2018
  80. KONSTAM MA
    Seeking therapeutic precision in heart failure: is ejection fraction really the way? Deconstructing the CHARM of heart failure with mid-range ejection fraction.
    Eur J Heart Fail. 2018 May 31. doi: 10.1002/ejhf.1205.
    PubMed     Text format    


  81. ROSSIGNOL P, Ferreira JP, Zannad F
    Fibrosis mechanistic phenotyping and antifibrotic response determination with biomarkers in heart failure: one single biomarker may not fit all settings.
    Eur J Heart Fail. 2018 May 31. doi: 10.1002/ejhf.1214.
    PubMed     Text format    


  82. GREENBERG B
    Mineralocorticoid receptor antagonists in heart failure: they work better when patients use them.
    Eur J Heart Fail. 2018 May 31. doi: 10.1002/ejhf.1222.
    PubMed     Text format    


  83. LAUFS U, Griese-Mammen N, Krueger K, Wachter A, et al
    PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study.
    Eur J Heart Fail. 2018 May 30. doi: 10.1002/ejhf.1213.
    PubMed     Text format     Abstract available


  84. NAGAI T, Sundaram V, Shoaib A, Shiraishi Y, et al
    Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan.
    Eur J Heart Fail. 2018 May 30. doi: 10.1002/ejhf.1210.
    PubMed     Text format     Abstract available


  85. KOMAJDA M, Bohm M, Borer JS, Ford I, et al
    Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis.
    Eur J Heart Fail. 2018 May 27. doi: 10.1002/ejhf.1234.
    PubMed     Text format     Abstract available


  86. CRESPO-LEIRO MG, Metra M, Lund LH, Milicic D, et al
    Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2018 May 27. doi: 10.1002/ejhf.1236.
    PubMed     Text format     Abstract available


  87. SHARMA A, Al-Khatib SM, Ezekowitz JA, Cooper LB, et al
    Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.
    Eur J Heart Fail. 2018 May 15. doi: 10.1002/ejhf.1192.
    PubMed     Text format     Abstract available


  88. KRISTENSEN SL, Rorth R, Jhund PS, Shen L, et al
    Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial.
    Eur J Heart Fail. 2018 May 4. doi: 10.1002/ejhf.1201.
    PubMed     Text format     Abstract available


  89. KORATALA A
    Metabolic abnormalities in heart failure patients treated with ultrafiltration versus diuretics.
    Eur J Heart Fail. 2018 May 3. doi: 10.1002/ejhf.1207.
    PubMed     Text format    



  90. Abstracts of the Heart Failure 2018 and the World Congress on Acute Heart Failure, 26-29 May 2018, Vienna, Austria.
    Eur J Heart Fail. 2018;20 Suppl 1:5-638.
    PubMed     Text format    


  91. MARTENS P, Dupont M, Mullens W
    Cardiac iron deficiency-how to refuel the engine out of fuel.
    Eur J Heart Fail. 2018;20:920-922.
    PubMed     Text format    


  92. FARMAKIS D, Mantzourani M, Filippatos G
    Anthracycline-induced cardiomyopathy: secrets and lies.
    Eur J Heart Fail. 2018;20:907-909.
    PubMed     Text format    


  93. GHIO S
    The need for evaluating right ventricular adaptation and ventriculo-arterial coupling: reply.
    Eur J Heart Fail. 2018;20:944-945.
    PubMed     Text format    


  94. PALAZZUOLI A, Ruocco G, Lombardi C
    The need for evaluating right ventricular adaptation and ventriculo-arterial coupling.
    Eur J Heart Fail. 2018;20:943-944.
    PubMed     Text format    


  95. PALAZZINI M, Dardi F, Galie N
    Pulmonary vascular disease due to left heart disease: how to achieve a more accurate approach beyond the haemodynamic phenotype: reply.
    Eur J Heart Fail. 2018;20:943.
    PubMed     Text format    


  96. GRIGNOLA JC, Trujillo P, Domingo E
    Pulmonary vascular disease due to left heart disease: how to achieve a more accurate approach beyond the haemodynamic phenotype.
    Eur J Heart Fail. 2018;20:942-943.
    PubMed     Text format    


    April 2018
  97. HARJOLA VP, Parissis J, Brunner-La Rocca HP, Celutkiene J, et al
    Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Ca
    Eur J Heart Fail. 2018 Apr 30. doi: 10.1002/ejhf.1204.
    PubMed     Text format     Abstract available


  98. RAVASSA S, Trippel T, Bach D, Bachran D, et al
    Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
    Eur J Heart Fail. 2018 Apr 30. doi: 10.1002/ejhf.1194.
    PubMed     Text format     Abstract available


  99. KAWADA T
    Psychosocial factors and mortality in patients with heart failure.
    Eur J Heart Fail. 2018 Apr 24. doi: 10.1002/ejhf.1208.
    PubMed     Text format    


  100. VAN VELDHUISEN DJ, Rienstra M, van der Meer P
    Value of digoxin in patients with heart failure: new pieces to the puzzle.
    Eur J Heart Fail. 2018 Apr 20. doi: 10.1002/ejhf.1200.
    PubMed     Text format    


  101. CERLINSKAITE K, Hollinger A, Mebazaa A, Cinotti R, et al
    Finding the balance between costs and quality in heart failure: a global challenge.
    Eur J Heart Fail. 2018 Apr 19. doi: 10.1002/ejhf.1195.
    PubMed     Text format    


  102. ALLA F, Agrinier N, Lavielle M, Rossignol P, et al
    Impact of the interruption of a large heart failure regional disease management programme on hospital admission rates: a population-based study.
    Eur J Heart Fail. 2018 Apr 16. doi: 10.1002/ejhf.1193.
    PubMed     Text format    


  103. DOEHNER W, Ural D, Celutkiene J
    Heart-brain interactions in patients with heart failure, including takotsubo syndrome: a need to monitor autonomic sympathetic activity: reply.
    Eur J Heart Fail. 2018 Apr 14. doi: 10.1002/ejhf.1177.
    PubMed     Text format    


  104. KLEBER FX, Koln PJ
    Oxygen consumption trajectory flattening-yet another cardiopulmonary exercise testing parameter in chronic heart failure.
    Eur J Heart Fail. 2018 Apr 14. doi: 10.1002/ejhf.1181.
    PubMed     Text format    


  105. GRODIN JL, Tang WHW
    I will take my heart failure 'lactate-free' please.
    Eur J Heart Fail. 2018 Apr 10. doi: 10.1002/ejhf.1190.
    PubMed     Text format    


  106. NORMAND C, Dickstein K
    Guideline recommendations for cardiac resynchronization therapy evolve but does clinical practice match the pace?
    Eur J Heart Fail. 2018;20:778-779.
    PubMed     Text format    


  107. MCMURRAY JJV
    Renin-angiotensin system inhibition-it's been a long but fruitful journey.
    Eur J Heart Fail. 2018;20:687-688.
    PubMed     Text format    


  108. VAN DEN BERGH WM, Droogh JM, Damman K
    You do something to me, something deep inside.
    Eur J Heart Fail. 2018;20:801-802.
    PubMed     Text format    


  109. HOWLETT JG
    The promise of patient-reported outcomes: one step closer to routine care.
    Eur J Heart Fail. 2018;20:697-699.
    PubMed     Text format    


  110. SINAGRA G, Fabris E
    Inflammation in cardiac amyloidosis: prognostic marker or therapeutic target?
    Eur J Heart Fail. 2018;20:758-759.
    PubMed     Text format    


    March 2018
  111. PACKER M
    Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure.
    Eur J Heart Fail. 2018 Mar 30. doi: 10.1002/ejhf.1185.
    PubMed     Text format     Abstract available


  112. FUDIM M, Mentz RJ
    Early versus late readmission during the vulnerable phase following hospitalization for heart failure: reply.
    Eur J Heart Fail. 2018 Mar 30. doi: 10.1002/ejhf.1189.
    PubMed     Text format    


  113. KIMURA M, Kohno T, Yoshikawa T
    Early versus late readmission during the vulnerable phase following hospitalization for heart failure.
    Eur J Heart Fail. 2018 Mar 30. doi: 10.1002/ejhf.1179.
    PubMed     Text format    


  114. SLIWA K, Petrie MC, Hilfiker-Kleiner D, Mebazaa A, et al
    Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy.
    Eur J Heart Fail. 2018 Mar 26. doi: 10.1002/ejhf.1178.
    PubMed     Text format     Abstract available


  115. SAVARESE G, Carrero JJ, Pitt B, Anker SD, et al
    Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2018 Mar 26. doi: 10.1002/ejhf.1182.
    PubMed     Text format     Abstract available


  116. PACKER M
    Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications.
    Eur J Heart Fail. 2018 Mar 22. doi: 10.1002/ejhf.1183.
    PubMed     Text format     Abstract available


  117. MAGKOUTIS N, Mantzaraki V, Farmakis D, Spathis A, et al
    Effects of functional electrical stimulation of lower limb muscles on circulating endothelial progenitor cells, CD34+ cells and vascular endothelial growth factor-A in heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2018 Mar 14. doi: 10.1002/ejhf.1176.
    PubMed     Text format    


  118. SEFEROVIC PM, Petrie MC, Filippatos GS, Anker SD, et al
    Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2018 Mar 8. doi: 10.1002/ejhf.1170.
    PubMed     Text format     Abstract available


  119. FERRARI R, Bueno H, Chioncel O, Cleland JG, et al
    Acute heart failure: lessons learned, roads ahead.
    Eur J Heart Fail. 2018 Mar 8. doi: 10.1002/ejhf.1169.
    PubMed     Text format    


  120. AVOGARO A, Fadini GP
    Insulin treatment in patients with diabetes and heart failure: defendant on the stand.
    Eur J Heart Fail. 2018 Mar 8. doi: 10.1002/ejhf.1161.
    PubMed     Text format    


  121. DEMISSEI BG, Voors AA
    Risk stratification in acute heart failure: reply.
    Eur J Heart Fail. 2018 Mar 7. doi: 10.1002/ejhf.1171.
    PubMed     Text format    


  122. SILISTE RN, Antohi EL, Pepoyan S, Nakou E, et al
    Anticoagulation in heart failure without atrial fibrillation: gaps and dilemmas in current clinical practice.
    Eur J Heart Fail. 2018 Mar 5. doi: 10.1002/ejhf.1153.
    PubMed     Text format     Abstract available


  123. WOLDMAN S
    Heart failure management-time to change our script on prognosis?
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1157.
    PubMed     Text format    


  124. PACKER M
    Derangements in adrenergic-adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction.
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1167.
    PubMed     Text format     Abstract available


  125. GRODIN JL, Carter S, Bart BA, Goldsmith SR, et al
    Direct comparison of ultrafiltration to pharmacological decongestion in heart failure: a per-protocol analysis of CARRESS-HF.
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1158.
    PubMed     Text format     Abstract available


  126. ABDUL-RAHIM AH, Shen L, Rush CJ, Jhund PS, et al
    Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction.
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1160.
    PubMed     Text format     Abstract available


  127. LUND LH, Pitt B
    Is hyperkalaemia in heart failure a risk factor or a risk marker? Implications for renin-angiotensin-aldosterone system inhibitor use.
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1175.
    PubMed     Text format    


  128. BANKE A, Fosbol EL, Moller JE, Gislason GH, et al
    Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial.
    Eur J Heart Fail. 2018 Mar 1. doi: 10.1002/ejhf.1168.
    PubMed     Text format     Abstract available


  129. VENTURA HO, Mehra MR
    Blood pressure and goal titration of neurohormonal antagonists: the tortoise wins again?
    Eur J Heart Fail. 2018;20:501-503.
    PubMed     Text format    


  130. MASSON S, Latini R
    HOME HF: an honest report of an (apparently) doable study.
    Eur J Heart Fail. 2018;20:481-482.
    PubMed     Text format    


  131. BARANDIARAN AIZPURUA A, Franssen FME, van Empel V, Brunner-La Rocca HP, et al
    An old debate still in the beta-phase?
    Eur J Heart Fail. 2018;20:557-559.
    PubMed     Text format    


  132. PETRIE MC, Connelly DT, Gardner RS
    Who needs an implantable cardioverter-defibrillator? Controversies and opportunities after DANISH.
    Eur J Heart Fail. 2018;20:413-416.
    PubMed     Text format    


  133. IKONOMIDIS I, Andreou I, Parissis J, Iliodromitis E, et al
    Prognostic significance of global longitudinal strain in chronic kidney disease: the evidence is building.
    Eur J Heart Fail. 2018;20:569-571.
    PubMed     Text format    


  134. BORIANI G, Malavasi VL
    Extending survival by reducing sudden death with implantable cardioverter-defibrillators: a challenging clinical issue in non-ischaemic and ischaemic cardiomyopathies.
    Eur J Heart Fail. 2018;20:420-426.
    PubMed     Text format    


  135. AFZAL A, Vallabhan RC, McCullough PA
    Acute kidney injury in cardiogenic shock: in search of early detection and clinical certainty.
    Eur J Heart Fail. 2018;20:582-584.
    PubMed     Text format    


  136. DEFILIPPIS EM, Keller SP, Morrow DA
    De-escalation of support with veno-arterial extracorporeal membrane oxygenation and Impella for cardiogenic shock.
    Eur J Heart Fail. 2018;20:621-622.
    PubMed     Text format    


  137. SCHULTE C, Schrage B, Pappalardo F, Westermann D, et al
    De-escalation of support with veno-arterial extracorporeal membrane oxygenation and Impella for cardiogenic shock: reply.
    Eur J Heart Fail. 2018;20:622-623.
    PubMed     Text format    


  138. BELLAVIA D, Iacovoni A
    Atrial fibrillation and right ventricular failure: reply.
    Eur J Heart Fail. 2018;20:620-621.
    PubMed     Text format    


  139. CURCIO A, De Rosa S, Indolfi C
    Should we rethink the indications for implantable cardioverter-defibrillators in non-ischaemic dilated cardiomyopathy?
    Eur J Heart Fail. 2018;20:417-419.
    PubMed     Text format    


  140. CERIT L
    Atrial fibrillation and right ventricular failure.
    Eur J Heart Fail. 2018;20:620.
    PubMed     Text format    


    February 2018
  141. COSMI F, Shen L, Magnoli M, Abraham WT, et al
    Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes.
    Eur J Heart Fail. 2018 Feb 28. doi: 10.1002/ejhf.1146.
    PubMed     Text format     Abstract available


  142. AMERI P, Canepa M, Anker MS, Belenkov Y, et al
    Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge.
    Eur J Heart Fail. 2018 Feb 21. doi: 10.1002/ejhf.1165.
    PubMed     Text format     Abstract available


  143. LINDGREN M, Eriksson P, Rosengren A, Robertson J, et al
    Cognitive performance in late adolescence and long-term risk of early heart failure in Swedish men.
    Eur J Heart Fail. 2018 Feb 19. doi: 10.1002/ejhf.1163.
    PubMed     Text format     Abstract available


  144. MADIAS JE
    Heart-brain interactions in patients with heart failure, including takotsubo syndrome: a need to monitor autonomic sympathetic activity.
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1150.
    PubMed     Text format    


  145. LEVY WC, Dardas TF
    Comparison of cardiopulmonary-based risk models with a clinical heart failure risk model.
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1164.
    PubMed     Text format    


  146. AKIYAMA E, Van Aelst LNL, Arrigo M, Lassus J, et al
    East Asia may have a better 1-year survival following an acute heart failure episode compared with Europe: results from an international observational cohort.
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1152.
    PubMed     Text format    


  147. ZYMLINSKI R, Biegus J, Sokolski M, Siwolowski P, et al
    Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion.
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1156.
    PubMed     Text format     Abstract available


  148. LUND LH, Claggett B, Liu J, Lam CS, et al
    Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1149.
    PubMed     Text format     Abstract available


  149. MOGENSEN UM, Gong J, Jhund PS, Shen L, et al
    Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
    Eur J Heart Fail. 2018 Feb 12. doi: 10.1002/ejhf.1139.
    PubMed     Text format     Abstract available


  150. COMIN-COLET J, Manito N, Segovia-Cubero J, Delgado J, et al
    Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
    Eur J Heart Fail. 2018 Feb 6. doi: 10.1002/ejhf.1145.
    PubMed     Text format     Abstract available


  151. ORBAN M, Besler C, Braun D, Nabauer M, et al
    Six-month outcome after transcatheter edge-to-edge repair of severe tricuspid regurgitation in patients with heart failure.
    Eur J Heart Fail. 2018 Feb 6. doi: 10.1002/ejhf.1147.
    PubMed     Text format     Abstract available


  152. POPOVIC D, Arena R, Guazzi M
    A flattening oxygen consumption trajectory phenotypes disease severity and poor prognosis in patients with heart failure with reduced, mid-range, and preserved ejection fraction.
    Eur J Heart Fail. 2018 Feb 6. doi: 10.1002/ejhf.1140.
    PubMed     Text format     Abstract available


  153. METRA M
    February 2018 at a glance: heart and brain interaction, prognostic variables, and acute heart failure and post-discharge outcomes.
    Eur J Heart Fail. 2018;20:191-192.
    PubMed     Text format    


  154. LEON JIMENEZ D, Gomez Huelgas R, Miramontes Gonzalez JP
    The mechanism of action of sodium-glucose co-transporter 2 inhibitors is similar to carbonic anhydrase inhibitors.
    Eur J Heart Fail. 2018;20:409.
    PubMed     Text format    


  155. SPIRITO P, Ferrazzi P
    We need more high-volume myectomy centres in Europe.
    Eur J Heart Fail. 2018;20:406-408.
    PubMed     Text format    


  156. ROSENKRANZ S, Hoeper MM
    Pulmonary vascular indices and survival in left heart disease: illusion of conclusion?
    Eur J Heart Fail. 2018;20:256-259.
    PubMed     Text format    


  157. LUND LH
    Optimizing outcomes after heart transplantation.
    Eur J Heart Fail. 2018;20:395-397.
    PubMed     Text format    


  158. STEVENSON LW, Schneiweiss S, Gilstrap L
    Propensity to match or mismatch patients and therapies?
    Eur J Heart Fail. 2018;20:355-358.
    PubMed     Text format    


    January 2018
  159. TROMP J, Voors AA, Lam CSP
    Heart failure with mid-range ejection fraction: causes and consequences.
    Eur J Heart Fail. 2018 Jan 16. doi: 10.1002/ejhf.1134.
    PubMed     Text format    


  160. TROMP J, van der Meer P
    Predicting heart failure: one size does not fit all.
    Eur J Heart Fail. 2018 Jan 15. doi: 10.1002/ejhf.1120.
    PubMed     Text format    


  161. LUND LH, Vedin O, Savarese G
    Is ejection fraction in heart failure a limitation or an opportunity?
    Eur J Heart Fail. 2018 Jan 15. doi: 10.1002/ejhf.1106.
    PubMed     Text format    


  162. TAMPAKAKIS E
    In search of markers of pulmonary vascular remodelling in pulmonary hypertension due to left heart disease.
    Eur J Heart Fail. 2018 Jan 15. doi: 10.1002/ejhf.1137.
    PubMed     Text format    


  163. COSTANZO MR
    Uric acid is important, but there is something that matters even more: to deliver sacubitril/valsartan to eligible heart failure patients.
    Eur J Heart Fail. 2018 Jan 12. doi: 10.1002/ejhf.1087.
    PubMed     Text format    


  164. ARQUES S
    Myocardial oedema and congestive heart failure: one piece of the puzzle?
    Eur J Heart Fail. 2018 Jan 12. doi: 10.1002/ejhf.1121.
    PubMed     Text format    


  165. BEUSEKAMP JC, Tromp J, van der Wal HH, Anker SD, et al
    Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.
    Eur J Heart Fail. 2018 Jan 12. doi: 10.1002/ejhf.1079.
    PubMed     Text format     Abstract available


  166. GORTER TM, de Boer RA
    Myocardial oedema and congestive heart failure: one piece of the puzzle? Reply.
    Eur J Heart Fail. 2018 Jan 10. doi: 10.1002/ejhf.1136.
    PubMed     Text format    


  167. DONAL E, Galli E
    Clinical relevance of spectral tissue Doppler-derived E/e' in the diagnosis of heart failure with preserved ejection fraction: reply.
    Eur J Heart Fail. 2018 Jan 8. doi: 10.1002/ejhf.1090.
    PubMed     Text format    


  168. LUND LH
    Complex relationships between co-morbidity, outcomes, and treatment effect in heart failure.
    Eur J Heart Fail. 2018 Jan 5. doi: 10.1002/ejhf.1107.
    PubMed     Text format    


  169. DE ROSA S, Eposito F, Carella C, Strangio A, et al
    Transcoronary concentration gradients of circulating microRNAs in heart failure.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1119.
    PubMed     Text format     Abstract available


  170. MCDONALD K, Troughton R, Dahlstrom U, Dargie H, et al
    Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1053.
    PubMed     Text format     Abstract available


  171. MELE D, Nardozza M, Ferrari R
    Left ventricular ejection fraction and heart failure: an indissoluble marriage?
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1071.
    PubMed     Text format    


  172. BREIDTHARDT T, Moreno-Weidmann Z, Uthoff H, Sabti Z, et al
    How accurate is clinical assessment of neck veins in the estimation of central venous pressure in acute heart failure? Insights from a prospective study.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1111.
    PubMed     Text format    


  173. AMBROSY AP, Fudim M, Chioncel O
    Sudden cardiac death following admission for acute heart failure: adding insult to injury.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1109.
    PubMed     Text format    


  174. FERREIRA JP, Duarte K, Pfeffer MA, McMurray JJV, et al
    Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarct
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1131.
    PubMed     Text format     Abstract available


  175. SUZUKI H, Matsumoto Y, Ota H, Sugimura K, et al
    Structural brain abnormalities and cardiac dysfunction in patients with chronic heart failure.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1104.
    PubMed     Text format    


  176. SOKORELI I, Pauws SC, Steyerberg EW, de Vries GJ, et al
    Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA-HF study.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1112.
    PubMed     Text format     Abstract available


  177. VADUGANATHAN M, Samman Tahhan A, Greene SJ, Okafor M, et al
    Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years.
    Eur J Heart Fail. 2018 Jan 4. doi: 10.1002/ejhf.1130.
    PubMed     Text format    


  178. PACKER M
    Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial.
    Eur J Heart Fail. 2018;20:49-51.
    PubMed     Text format    


  179. SWEDBERG K
    Lessons for the monitoring of safety in clinical trials.
    Eur J Heart Fail. 2018;20:148.
    PubMed     Text format    


  180. CRESPO-LEIRO MG, Barge-Caballero E
    Heart transplantation and left ventricular assist systems. Not too early, not too late.
    Eur J Heart Fail. 2018;20:161-163.
    PubMed     Text format    


  181. BAR C, Thum T
    A long way for microRNAs to become meaningful prognostic biomarkers.
    Eur J Heart Fail. 2018;20:76-77.
    PubMed     Text format    


  182. GUSTAFSSON F
    Management of patients with cardiogenic shock on temporary mechanical circulatory support: urgent transplantation or on to the next pump?
    Eur J Heart Fail. 2018;20:187-189.
    PubMed     Text format    


  183. METRA M
    January 2018 at a glance: biomarkers, co-morbidities and mechanical circulatory support.
    Eur J Heart Fail. 2018;20:1-2.
    PubMed     Text format    


  184. AVOGARO A
    Keeping the right track in the treatment of patients with type 2 diabetes.
    Eur J Heart Fail. 2018;20:52-54.
    PubMed     Text format    


  185. NAGUEH SF
    Non-invasive assessment of left ventricular filling pressure.
    Eur J Heart Fail. 2018;20:38-48.
    PubMed     Text format     Abstract available


  186. BARGE-CABALLERO E, Almenar-Bonet L, Gonzalez-Vilchez F, Lambert-Rodriguez JL, et al
    Clinical outcomes of temporary mechanical circulatory support as a direct bridge to heart transplantation: a nationwide Spanish registry.
    Eur J Heart Fail. 2018;20:178-186.
    PubMed     Text format     Abstract available


    December 2017
  187. TKACZYSZYN M, Jankowska EA
    Iron deficiency and red cell indices in patients with heart failure: reply.
    Eur J Heart Fail. 2017 Dec 27. doi: 10.1002/ejhf.1092.
    PubMed     Text format    


  188. DOEHNER W, Ural D, Haeusler KG, Celutkiene J, et al
    Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association.
    Eur J Heart Fail. 2017 Dec 27. doi: 10.1002/ejhf.1100.
    PubMed     Text format     Abstract available


  189. ROSANO GMC, Seferovic P, Farmakis D, Filippatos G, et al
    Renin inhibition in heart failure and diabetes: the real story.
    Eur J Heart Fail. 2017 Dec 22. doi: 10.1002/ejhf.1072.
    PubMed     Text format    


  190. XANTHOPOULOS A, Tryposkiadis K, Giamouzis G, Konstantinou D, et al
    Larissa Heart Failure Risk Score: a proposed simple score for risk stratification in chronic heart failure.
    Eur J Heart Fail. 2017 Dec 22. doi: 10.1002/ejhf.1132.
    PubMed     Text format    


  191. RAMALHO SHR, Shah AM
    Central sleep apnoea in heart failure with reduced ejection fraction, adaptive servo-ventilation, and left ventricular ejection fraction: the (still) missing link.
    Eur J Heart Fail. 2017 Dec 22. doi: 10.1002/ejhf.1108.
    PubMed     Text format    


  192. POKORNEY SD, Al-Khatib SM, Sun JL, Schulte P, et al
    Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF.
    Eur J Heart Fail. 2017 Dec 20. doi: 10.1002/ejhf.1078.
    PubMed     Text format     Abstract available


  193. VAN AELST LNL, Arrigo M, Placido R, Akiyama E, et al
    Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion.
    Eur J Heart Fail. 2017 Dec 18. doi: 10.1002/ejhf.1050.
    PubMed     Text format     Abstract available


  194. BISTOLA V, Polyzogopoulou E, Ikonomidis I, Parissis J, et al
    Congestion in acute heart failure with reduced vs. preserved left ventricular ejection fraction: differences, similarities and remaining gaps.
    Eur J Heart Fail. 2017 Dec 18. doi: 10.1002/ejhf.1115.
    PubMed     Text format    


  195. EMMENS JE, Jones DJL, Cao TH, Chan DCS, et al
    Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure.
    Eur J Heart Fail. 2017 Dec 18. doi: 10.1002/ejhf.1101.
    PubMed     Text format     Abstract available


  196. LUPON J, Bayes-Genis A
    Left ventricular ejection fraction in heart failure: a clinician's perspective about a dynamic and imperfect parameter, though still convenient and a cornerstone for patient classification and management.
    Eur J Heart Fail. 2017 Dec 18. doi: 10.1002/ejhf.1116.
    PubMed     Text format    


  197. DELLES C, Rankin NJ, Boachie C, McConnachie A, et al
    Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997.
    Eur J Heart Fail. 2017 Dec 11. doi: 10.1002/ejhf.1076.
    PubMed     Text format     Abstract available


  198. BHAMBHANI V, Kizer JR, Lima JAC, van der Harst P, et al
    Predictors and outcomes of heart failure with mid-range ejection fraction.
    Eur J Heart Fail. 2017 Dec 11. doi: 10.1002/ejhf.1091.
    PubMed     Text format     Abstract available


  199. VON HAEHLING S
    Co-morbidities in heart failure beginning to sprout-and no end in sight?
    Eur J Heart Fail. 2017;19:1566-1568.
    PubMed     Text format    


    November 2017
  200. COWIE MR, Woehrle H, Wegscheider K, Vettorazzi E, et al
    Adaptive servo-ventilation for central sleep apnoea in systolic heart failure: results of the major substudy of SERVE-HF.
    Eur J Heart Fail. 2017 Nov 30. doi: 10.1002/ejhf.1048.
    PubMed     Text format     Abstract available


  201. KHERA R, Pandey A
    The heart failure readmission quagmire: taking a deep dive to find solutions.
    Eur J Heart Fail. 2017 Nov 30. doi: 10.1002/ejhf.1082.
    PubMed     Text format    


  202. ARQUES S
    Clinical relevance of spectral tissue Doppler-derived E/e' in the diagnosis of heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Nov 30. doi: 10.1002/ejhf.1084.
    PubMed     Text format    


  203. WOLSK E, Claggett B, Kober L, Pocock S, et al
    Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
    Eur J Heart Fail. 2017 Nov 30. doi: 10.1002/ejhf.1073.
    PubMed     Text format     Abstract available


  204. SENNI M, McMurray JJV, Wachter R, McIntyre HF, et al
    Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study.
    Eur J Heart Fail. 2017 Nov 22. doi: 10.1002/ejhf.1054.
    PubMed     Text format     Abstract available


  205. ROSSING K, Gustafsson F
    Medical and mechanical unloading in advanced heart failure: hope for cardiac recovery?
    Eur J Heart Fail. 2017 Nov 21. doi: 10.1002/ejhf.1081.
    PubMed     Text format    


  206. TAVAZZI L
    It's time to move on from counting co-morbidities to curing them: the case of chronic heart failure-chronic obstructive pulmonary disease co-morbidity.
    Eur J Heart Fail. 2017 Nov 21. doi: 10.1002/ejhf.1083.
    PubMed     Text format    


  207. GREENE SJ, Felker GM
    Considering the duration of heart failure: using the past to predict the future.
    Eur J Heart Fail. 2017 Nov 21. doi: 10.1002/ejhf.1064.
    PubMed     Text format    


  208. FARMAKIS D, Papingiotis G, Parissis J, Filippatos G, et al
    Ups and downs in heart failure: the case of proteomics.
    Eur J Heart Fail. 2017 Nov 21. doi: 10.1002/ejhf.1065.
    PubMed     Text format    


  209. SESSA M, Mascolo A, Mortensen RN, Andersen MP, et al
    Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
    Eur J Heart Fail. 2017 Nov 20. doi: 10.1002/ejhf.1045.
    PubMed     Text format     Abstract available


  210. RORTH R, Fosbol EL, Mogensen UM, Kragholm K, et al
    Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1046.
    PubMed     Text format     Abstract available


  211. GO YY, Sugimoto T, Bulluck H, Acharyya S, et al
    Age and ejection fraction modify the impact of atrial fibrillation on acute heart failure outcomes.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1075.
    PubMed     Text format    


  212. PALAU P, Dominguez E, Nunez J
    Clinical utility of cardiopulmonary exercise testing in patients with heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1066.
    PubMed     Text format    


  213. LOURENCO AP, Leite-Moreira AF, Balligand JL, Bauersachs J, et al
    An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1059.
    PubMed     Text format     Abstract available


  214. SELVARAJ S, Claggett B, Shah SJ, Anand I, et al
    Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1060.
    PubMed     Text format     Abstract available


  215. GHIO S, Crimi G, Temporelli PL, Traversi E, et al
    Haemodynamic effects of an acute vasodilator challenge in heart failure patients with reduced ejection fraction and different forms of post-capillary pulmonary hypertension.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1067.
    PubMed     Text format     Abstract available


  216. ZENG DX
    Iron deficiency and red cell indices in patients with heart failure.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1052.
    PubMed     Text format    


  217. SCHNEIDER D, Flores D, Mueller C
    Risk stratification in acute heart failure.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002/ejhf.1057.
    PubMed     Text format    


  218. VADUGANATHAN M, Cheema B, Cleveland E, Sankar K, et al
    Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial.
    Eur J Heart Fail. 2017 Nov 16. doi: 10.1002.
    PubMed     Text format     Abstract available


  219. ARRIGO M, Mebazaa A
    Addressing vulnerability: opening a new door to improved outcomes in acute heart failure.
    Eur J Heart Fail. 2017 Nov 9. doi: 10.1002/ejhf.1063.
    PubMed     Text format    


  220. LAL S, Kotchetkova I, Cao J, Jackson D, et al
    Heart failure admissions and poor subsequent outcomes in adults with congenital heart disease.
    Eur J Heart Fail. 2017 Nov 7. doi: 10.1002/ejhf.1051.
    PubMed     Text format    


  221. CATINO AB, Ferrin P, Wever-Pinzon J, Horne BD, et al
    Clinical and histopathological effects of heart failure drug therapy in advanced heart failure patients on chronic mechanical circulatory support.
    Eur J Heart Fail. 2017 Nov 1. doi: 10.1002/ejhf.1018.
    PubMed     Text format     Abstract available


    October 2017
  222. PACKER M
    Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?
    Eur J Heart Fail. 2017 Oct 30. doi: 10.1002/ejhf.1047.
    PubMed     Text format    


  223. CHEEMA B, Ambrosy AP, Kaplan RM, Senni M, et al
    Lessons learned in acute heart failure.
    Eur J Heart Fail. 2017 Oct 29. doi: 10.1002/ejhf.1042.
    PubMed     Text format     Abstract available


  224. FUDIM M, O'Connor CM, Dunning A, Ambrosy AP, et al
    Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF.
    Eur J Heart Fail. 2017 Oct 29. doi: 10.1002/ejhf.1020.
    PubMed     Text format     Abstract available


  225. GREENE SJ, Mentz RJ
    Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'?
    Eur J Heart Fail. 2017 Oct 29. doi: 10.1002/ejhf.1024.
    PubMed     Text format    


  226. KELLY JP, DeVore AD
    Can walking patients with heart failure and preserved ejection fraction tell us who should walk also to the catheterization laboratory or just walk home?
    Eur J Heart Fail. 2017 Oct 29. doi: 10.1002/ejhf.1041.
    PubMed     Text format    


  227. BAJAJ NS, Claggett B, Lewis EF, Desai AS, et al
    Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Oct 25. doi: 10.1002/ejhf.1040.
    PubMed     Text format    


  228. NAUTA JF, Hummel YM, van Melle JP, van der Meer P, et al
    What have we learned about heart failure with mid-range ejection fraction one year after its introduction?
    Eur J Heart Fail. 2017 Oct 24. doi: 10.1002/ejhf.1058.
    PubMed     Text format     Abstract available


  229. PANICO C, Condorelli G
    microRNA-132: a new biomarker of heart failure at last?
    Eur J Heart Fail. 2017 Oct 20. doi: 10.1002/ejhf.1044.
    PubMed     Text format    


  230. PACKER M
    Why is the use of digitalis withering? Another reason that we need medical heart failure specialists.
    Eur J Heart Fail. 2017 Oct 19. doi: 10.1002/ejhf.1043.
    PubMed     Text format    


  231. STEWART COATS AJ
    Intravenous ferric carboxymaltose for heart failure with iron deficiency.
    Eur J Heart Fail. 2017 Oct 19. doi: 10.1002/ejhf.1027.
    PubMed     Text format    


  232. ROY B, Woo M, Kumar R
    Cerebral blood flow in central autonomic network: is there any effect of hemispheric lateralization in patients with heart failure? Reply.
    Eur J Heart Fail. 2017 Oct 18. doi: 10.1002/ejhf.1033.
    PubMed     Text format    


  233. GREENE SJ, Butler J, Fonarow GC, Subacius HP, et al
    Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial.
    Eur J Heart Fail. 2017 Oct 17. doi: 10.1002/ejhf.1019.
    PubMed     Text format     Abstract available


  234. DE BUYZERE ML
    Multi-biomarker risk stratification in heart failure: a story of diminished marginal returns after Herculean efforts?
    Eur J Heart Fail. 2017 Oct 17. doi: 10.1002/ejhf.1035.
    PubMed     Text format    


  235. GORTER TM, van Veldhuisen DJ, Bauersachs J, Borlaug BA, et al
    Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2017 Oct 16. doi: 10.1002/ejhf.1029.
    PubMed     Text format     Abstract available


  236. MAISANO F, Ruschitzka F
    Mitral interventions in heart failure: time to deliver on the promise.
    Eur J Heart Fail. 2017 Oct 16. doi: 10.1002.
    PubMed     Text format    


  237. MIRO O, Tost J, Gil V, Martin-Sanchez FJ, et al
    The BRONCH-AHF study: effects on short-term outcome of nebulized bronchodilators in emergency department patients diagnosed with acute heart failure.
    Eur J Heart Fail. 2017 Oct 16. doi: 10.1002/ejhf.1028.
    PubMed     Text format    


  238. SHARMA K, Tedford RJ
    Atrial fibrillation in heart failure with preserved ejection fraction: time to address the chicken and the egg.
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002.
    PubMed     Text format    


  239. BOHM M, Komajda M, Borer JS, Ford I, et al
    Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT.
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002/ejhf.1021.
    PubMed     Text format     Abstract available


  240. LA ROVERE MT, Maestri R, Robbi E, Caporotondi A, et al
    Daytime periodic breathing during short-term laboratory recordings in heart failure patients: the iceberg tip of central sleep apnoea?
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002/ejhf.1031.
    PubMed     Text format    


  241. MASSON S, Batkai S, Beermann J, Bar C, et al
    Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure.
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002.
    PubMed     Text format     Abstract available


  242. MORTARA A
    Inotropes and vasopressors in acute heart failure, when the devil dresses as an angel.
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002/ejhf.1037.
    PubMed     Text format    


  243. GREENBERG B
    Jumping down the rabbit hole: unravelling the right ventricle in heart failure.
    Eur J Heart Fail. 2017 Oct 12. doi: 10.1002.
    PubMed     Text format    


  244. HANBERG JS, Rao VS, Ahmad T, Chunara Z, et al
    Inflammation and cardio-renal interactions in heart failure: a potential role for interleukin-6.
    Eur J Heart Fail. 2017 Oct 11. doi: 10.1002.
    PubMed     Text format    


  245. KAYE DM, Silvestry FE, Gustafsson F, Cleland JG, et al
    Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction.
    Eur J Heart Fail. 2017 Oct 11. doi: 10.1002.
    PubMed     Text format     Abstract available


  246. AGOSTONI P, Guazzi M
    Exercise ventilatory inefficiency in heart failure: some fresh news into the roadmap of heart failure with preserved ejection fraction phenotyping.
    Eur J Heart Fail. 2017 Oct 9. doi: 10.1002.
    PubMed     Text format    


  247. MEBAZAA A, Motiejunaite J, Gayat E, Crespo-Leiro MG, et al
    Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2017 Oct 8. doi: 10.1002.
    PubMed     Text format     Abstract available


  248. VAN ITERSON EH, Johnson BD, Borlaug BA, Olson TP, et al
    Physiological dead space and arterial carbon dioxide contributions to exercise ventilatory inefficiency in patients with reduced or preserved ejection fraction heart failure.
    Eur J Heart Fail. 2017 Oct 8. doi: 10.1002.
    PubMed     Text format     Abstract available


  249. NUNEZ J, Sanchis J, Bayes-Genis A
    Iron status measurement in routine heart failure assessment: a call for action.
    Eur J Heart Fail. 2017 Oct 8. doi: 10.1002.
    PubMed     Text format    


  250. HUMMEL YM, Liu LCY, Lam CSP, Fonseca-Munoz DF, et al
    Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements.
    Eur J Heart Fail. 2017 Oct 6. doi: 10.1002.
    PubMed     Text format     Abstract available


  251. SAVARESE G, Lund LH
    Up-titrating angiotensin-converting enzyme inhibitors in heart failure: evidence and challenges.
    Eur J Heart Fail. 2017 Oct 5. doi: 10.1002.
    PubMed     Text format    


  252. LAM PH, Dooley DJ, Fonarow GC, Butler J, et al
    Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.
    Eur J Heart Fail. 2017 Oct 5. doi: 10.1002.
    PubMed     Text format     Abstract available


  253. STENEMO M, Nowak C, Byberg L, Sundstrom J, et al
    Circulating proteins as predictors of incident heart failure in the elderly.
    Eur J Heart Fail. 2017 Oct 2. doi: 10.1002.
    PubMed     Text format     Abstract available


  254. METRA M
    October 2017 at a glance: phenotyping heart failure, co-morbidities, use of evidence-based therapy and new treatments.
    Eur J Heart Fail. 2017;19:1216-1217.
    PubMed     Text format    


  255. TAVAZZI L
    A brief overview of cardiac resynchronization therapy and its current use in clinical practice.
    Eur J Heart Fail. 2017;19:1280-1283.
    PubMed     Text format    


  256. CHEEMA BS, Sabbah HN, Greene SJ, Gheorghiade M, et al
    Protein turnover in the failing heart: an ever-changing landscape.
    Eur J Heart Fail. 2017;19:1218-1221.
    PubMed     Text format    


  257. SOMMER A, Kronborg MB, Nielsen JC
    Guided left ventricular lead placement for cardiac resynchronization therapy - an opportunity for image integration: reply.
    Eur J Heart Fail. 2017;19:1344.
    PubMed     Text format    


    September 2017
  258. MOTIEJUNAITE J, Celutkiene J, Mebazaa A
    The right ventricle drives the progression of heart failure.
    Eur J Heart Fail. 2017 Sep 29. doi: 10.1002.
    PubMed     Text format    


  259. WELSH P, Kou L, Yu C, Anand I, et al
    Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study.
    Eur J Heart Fail. 2017 Sep 27. doi: 10.1002.
    PubMed     Text format     Abstract available


  260. LUND LH, Trochu JN, Meyns B, Caliskan K, et al
    Screening for heart transplantation and left ventricular assist system: results from the ScrEEning for advanced Heart Failure treatment (SEE-HF) study.
    Eur J Heart Fail. 2017 Sep 27. doi: 10.1002.
    PubMed     Text format     Abstract available


  261. LUPON J, Simpson J, McMurray JJV, de Antonio M, et al
    Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format    


  262. AGOSTONI P, Paolillo S, Mapelli M, Gentile P, et al
    Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format     Abstract available


  263. LUND LH, Svennblad B, Dahlstrom U, Stahlberg M, et al
    Effect of expanding evidence and evolving clinical guidelines on the prevalence of indication for cardiac resynchronization therapy in patients with heart failure.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format     Abstract available


  264. VAN BILSEN M, Patel HC, Bauersachs J, Bohm M, et al
    The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format     Abstract available


  265. CANEPA M, Straburzynska-Migaj E, Drozdz J, Fernandez-Vivancos C, et al
    Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format     Abstract available


  266. BAYES-GENIS A, Lanfear DE, de Ronde MWJ, Lupon J, et al
    Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format     Abstract available


  267. HAWKINS NM
    Chronic obstructive pulmonary disease and heart failure in Europe-further evidence of the need for integrated care.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format    


  268. WOLSK E, Kaye D, Borlaug BA, Burkhoff D, et al
    Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction.
    Eur J Heart Fail. 2017 Sep 26. doi: 10.1002.
    PubMed     Text format     Abstract available


  269. VINEREANU D, Margulescu AD
    The fallacy of resting echocardiographic parameters of cardiac function in heart failure with preserved ejection fraction: reply.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format    


  270. VAN BOVEN N, Kardys I, van Vark LC, Akkerhuis KM, et al
    Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format     Abstract available


  271. KOH AS, Tay WT, Teng THK, Vedin O, et al
    A comprehensive population-based characterization of heart failure with mid-range ejection fraction.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format     Abstract available


  272. BAYES-GENIS A, Nunez J, Lupon J
    Heart failure with mid-range ejection fraction: a transition phenotype?
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format    


  273. SANDERSON JE, Fang F, Wei YX
    The fallacy of resting echocardiographic parameters of cardiac function in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format    


  274. WONG LL, Richards AM
    Harnessing the power of microRNAs as prognostic biomarkers in acute heart failure.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format    


  275. TOMPKINS BA, Rieger AC, Florea V, Banerjee MN, et al
    New insights into cell-based therapy for heart failure from the CHART-1 study.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format    


  276. KRISTENSEN SL, Mogensen UM, Tarnesby G, Gimpelewicz CR, et al
    Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial.
    Eur J Heart Fail. 2017 Sep 25. doi: 10.1002.
    PubMed     Text format     Abstract available


  277. MARTENS P, Verbrugge FH, Nijst P, Dupont M, et al
    Limited contractile reserve contributes to poor peak exercise capacity in iron-deficient heart failure.
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed     Text format    


  278. CORRA U, Agostoni PG, Anker SD, Coats AJS, et al
    Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed     Text format     Abstract available


  279. SQUIRE IB
    Biomarkers and prognostication in heart failure with reduced and preserved ejection fraction: similar but different?
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed     Text format    


  280. BUTLER J, Stockbridge N, Gheorghiade M
    Past, present, and future of acute heart failure clinical trials-a high-risk population in search of a strategy.
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed     Text format    


  281. NAGAI M, Dote K, Masaya M
    Cerebral blood flow in the central autonomic network: is there any effect of hemispheric lateralization in patients with heart failure?
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed     Text format    


  282. GIRERD N, Rossignol P
    Performing lung ultrasound at rest and/or after an exercise stress test to better identify high-risk ambulatory patients with heart failure.
    Eur J Heart Fail. 2017 Sep 18. doi: 10.1002.
    PubMed     Text format    


  283. RAPEZZI C, Milandri A, Lorenzini M
    The complex interplay between systolic and diastolic function at rest and during exercise in heart failure: the case of cardiac amyloidosis.
    Eur J Heart Fail. 2017 Sep 14. doi: 10.1002.
    PubMed     Text format    


  284. PATEL JN, Shah SJ
    Inorganic vs. organic nitrates for heart failure with preserved ejection fraction: it's not all in your head!
    Eur J Heart Fail. 2017 Sep 11. doi: 10.1002.
    PubMed     Text format    


  285. TRIPPEL TD, Van Linthout S, Westermann D, Lindhorst R, et al
    Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide vs. furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
    Eur J Heart Fail. 2017 Sep 11. doi: 10.1002.
    PubMed     Text format     Abstract available


  286. KALOGEROPOULOS AP, Butler J
    Heart rate in heart failure with preserved ejection fraction: target or marker?
    Eur J Heart Fail. 2017 Sep 11. doi: 10.1002.
    PubMed     Text format    


  287. ZHANG Y, Bauersachs J, Langer HF
    Immune mechanisms in heart failure.
    Eur J Heart Fail. 2017 Sep 11. doi: 10.1002.
    PubMed     Text format     Abstract available


  288. STEWART S
    Home is where the heart is when it comes to transitional care in heart failure, but is it the only way to improve health outcomes?
    Eur J Heart Fail. 2017 Sep 10. doi: 10.1002.
    PubMed     Text format    


  289. PACKER M
    How have millions of people with heart failure benefited from our research over the last 10-15 years? The sounds of dead silence.
    Eur J Heart Fail. 2017 Sep 10. doi: 10.1002.
    PubMed     Text format    


  290. INOHARA T, Vemulapalli S
    Percutaneous edge-to-edge leaflet repair: a solution to the risk-treatment paradox of mitral regurgitation complicated by pulmonary hypertension?
    Eur J Heart Fail. 2017 Sep 10. doi: 10.1002.
    PubMed     Text format    


  291. BOSCH L, Carluccio E, Coiro S, Gong L, et al
    Risk stratification of Asian patients with heart failure and reduced ejection fraction: the effectiveness of the Echo Heart Failure Score.
    Eur J Heart Fail. 2017 Sep 7. doi: 10.1002.
    PubMed     Text format    


  292. PLATZ E, Jhund PS, Claggett BL, Pfeffer MA, et al
    Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality.
    Eur J Heart Fail. 2017 Sep 4. doi: 10.1002.
    PubMed     Text format     Abstract available


  293. BIERING-SORENSEN T, Querejeta Roca G, Hegde SM, Shah AM, et al
    Left ventricular ejection time is an independent predictor of incident heart failure in a community-based cohort.
    Eur J Heart Fail. 2017 Sep 4. doi: 10.1002.
    PubMed     Text format     Abstract available


  294. WAGENAAR KP, Rutten FH, Klompstra L, Bhana Y, et al
    'heartfailurematters.org', an educational website for patients and carers from the Heart Failure Association of the European Society of Cardiology: objectives, use and future directions.
    Eur J Heart Fail. 2017 Sep 4. doi: 10.1002.
    PubMed     Text format     Abstract available


  295. COTTER G, Metra M, Davison BA, Jondeau G, et al
    Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?
    Eur J Heart Fail. 2017 Sep 4. doi: 10.1002.
    PubMed     Text format     Abstract available


    August 2017
  296. D'ANGIOLELLA LS, Cortesi PA, Pitotti C, Ritrovato D, et al
    Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context.
    Eur J Heart Fail. 2017 Aug 28. doi: 10.1002.
    PubMed     Text format    


  297. GOHAR A, Chong JPC, Liew OW, den Ruijter H, et al
    The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
    Eur J Heart Fail. 2017 Aug 28. doi: 10.1002.
    PubMed     Text format     Abstract available


  298. GAYAT E, Arrigo M, Littnerova S, Sato N, et al
    Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study.
    Eur J Heart Fail. 2017 Aug 28. doi: 10.1002.
    PubMed     Text format     Abstract available


  299. COTTER G, Cohen-Solal A, Davison BA, Mebazaa A, et al
    RELAX-AHF, BLAST-AHF, TRUE-AHF, and other important truths in acute heart failure research.
    Eur J Heart Fail. 2017 Aug 24. doi: 10.1002.
    PubMed     Text format    


  300. ZAMORA E, Lupon J, Bayes-Genis A
    Obesity in heart failure: is it time to rethink the paradox? Reply.
    Eur J Heart Fail. 2017 Aug 24. doi: 10.1002.
    PubMed     Text format    


  301. BUTLER J, Hamo CE, Filippatos G, Pocock SJ, et al
    The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.
    Eur J Heart Fail. 2017 Aug 24. doi: 10.1002.
    PubMed     Text format     Abstract available


  302. GREENBERG B
    Gene therapy for heart failure: time to go back to the drawing board.
    Eur J Heart Fail. 2017 Aug 24. doi: 10.1002.
    PubMed     Text format    


  303. MAGNUSSEN H, Canepa M, Zambito PE, Brusasco V, et al
    What can we learn from pulmonary function testing in heart failure?
    Eur J Heart Fail. 2017 Aug 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  304. PARISSIS J, Bistola V, Ikonomidis I, Triposkiadis F, et al
    Nitroxyl donors for acute heart failure: promising newcomers.
    Eur J Heart Fail. 2017 Aug 14. doi: 10.1002.
    PubMed     Text format    


  305. AMBROSY AP, Gheorghiade M
    Clinical profiles in acute heart failure: one size fits all or not at all?
    Eur J Heart Fail. 2017 Aug 8. doi: 10.1002.
    PubMed     Text format    


  306. AMBROSY AP, Gheorghiade M
    Real-world dosing of evidence-based medications for heart failure: embracing guideline recommendations and clinical judgement.
    Eur J Heart Fail. 2017 Aug 8. doi: 10.1002.
    PubMed     Text format    


  307. METRA M
    August 2017 at a glance: tailored treatment, acute heart failure and cardiac resynchronization.
    Eur J Heart Fail. 2017;19:969-970.
    PubMed     Text format    


    July 2017
  308. COGSWELL RJ, Norby FL, Gottesman RF, Chen LY, et al
    High prevalence of subclinical cerebral infarction in patients with heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Jul 24. doi: 10.1002.
    PubMed     Text format     Abstract available


  309. TITA C, Gilbert EM, Van Bakel AB, Grzybowski J, et al
    A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2017 Jul 5. doi: 10.1002.
    PubMed     Text format     Abstract available


    June 2017
  310. AMBROSY AP, Butler J, Gheorghiade M
    Clinical trials in acute heart failure: beginning of the end or end of the beginning?
    Eur J Heart Fail. 2017 Jun 28. doi: 10.1002.
    PubMed     Text format    


  311. BURNS KV, Gage RM, Curtin AE, Gorcsan J 3rd, et al
    Left ventricular-only pacing in heart failure patients with normal atrioventricular conduction improves global function and left ventricular regional mechanics compared with biventricular pacing: an adaptive cardiac resynchronization therapy sub-study
    Eur J Heart Fail. 2017 Jun 26. doi: 10.1002.
    PubMed     Text format     Abstract available


  312. SHARMA A, Demissei BG, Tromp J, Hillege HL, et al
    A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure.
    Eur J Heart Fail. 2017 Jun 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  313. STEWART S
    Persistently misunderstood and malignant: the case of heart failure vs. cancer.
    Eur J Heart Fail. 2017 Jun 19. doi: 10.1002.
    PubMed     Text format    


  314. NIKOLOVSKA VUKADINOVIC A, Vukadinovic D, Borer J, Cowie M, et al
    Heart rate and its reduction in chronic heart failure and beyond.
    Eur J Heart Fail. 2017 Jun 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  315. RASTOGI A, Novak E, Platts AE, Mann DL, et al
    Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction.
    Eur J Heart Fail. 2017 Jun 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  316. ZAMAN S, Zaman SS, Scholtes T, Shun-Shin MJ, et al
    The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets.
    Eur J Heart Fail. 2017 Jun 8. doi: 10.1002.
    PubMed     Text format     Abstract available


  317. BOHM M, Laufs U, Mahfoud F, Schirmer SH, et al
    Primum non nocere: the dangers of deferring heart failure therapy.
    Eur J Heart Fail. 2017 Jun 8. doi: 10.1002.
    PubMed     Text format    


  318. BOSCH L, Lam CSP, Gong L, Chan SP, et al
    Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction.
    Eur J Heart Fail. 2017 Jun 8. doi: 10.1002.
    PubMed     Text format     Abstract available


  319. MUELLER C
    Clinical utility of biomarkers in heart failure.
    Eur J Heart Fail. 2017 Jun 5. doi: 10.1002.
    PubMed     Text format    


  320. LASSUS J
    Evaluating pulmonary congestion with lung ultrasound and the need to take the next steps in heart failure.
    Eur J Heart Fail. 2017 Jun 5. doi: 10.1002.
    PubMed     Text format    


  321. DEVORE AD, Hernandez AF
    Improving heart failure health: is there a secret Swedish sauce?
    Eur J Heart Fail. 2017 Jun 5. doi: 10.1002.
    PubMed     Text format    


  322. FERREIRA JP, Rossignol P, Machu JL, Sharma A, et al
    Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.
    Eur J Heart Fail. 2017 Jun 5. doi: 10.1002.
    PubMed     Text format     Abstract available


  323. HERRERO-PUENTE P, Prieto-Garcia B, Garcia-Garcia M, Llorens P, et al
    The relationship of circulating relaxin-2 concentrations with short-term prognosis in patients with acute heart failure: the RELAHF study.
    Eur J Heart Fail. 2017 Jun 5. doi: 10.1002.
    PubMed     Text format     Abstract available


  324. FILIPPATOS G, Maggioni AP, Lam CSP, Pieske-Kraigher E, et al
    Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.
    Eur J Heart Fail. 2017;19:782-791.
    PubMed     Text format     Abstract available


    May 2017
  325. TEERLINK JR, Metra M, Filippatos GS, Davison BA, et al
    Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study.
    Eur J Heart Fail. 2017 May 31. doi: 10.1002.
    PubMed     Text format     Abstract available


  326. DE CATERINA R
    Aspirin in heart failure: don't throw the baby (aspirin) out with the bathwater.
    Eur J Heart Fail. 2017 May 31. doi: 10.1002.
    PubMed     Text format    


  327. AHMED A, Blackman MR, White M, Anker SD, et al
    Emphasis on abdominal obesity as a modifier of eplerenone effect in heart failure: hypothesis-generating signals from EMPHASIS-HF.
    Eur J Heart Fail. 2017 May 30. doi: 10.1002.
    PubMed     Text format    


  328. ROY B, Woo MA, Wang DJJ, Fonarow GC, et al
    Reduced regional cerebral blood flow in patients with heart failure.
    Eur J Heart Fail. 2017 May 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  329. HARJOLA VP, Mullens W, Banaszewski M, Bauersachs J, et al
    Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur J Heart Fail. 2017 May 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  330. PLATZ E, Merz AA, Jhund PS, Vazir A, et al
    Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review.
    Eur J Heart Fail. 2017 May 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  331. VEGTER EL, van der Meer P, Voors AA
    Associations between volume status and circulating microRNAs in acute heart failure.
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed     Text format    


  332. CHIRINOS JA, Londono-Hoyos F, Zamani P, Beraun M, et al
    Effects of organic and inorganic nitrate on aortic and carotid haemodynamics in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed     Text format     Abstract available


  333. POPESCU BA, Beladan CC, Popescu AC
    Mechanical dyssynchrony in heart failure with preserved ejection fraction: a treatment target or a dead end?
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed     Text format    


  334. METRA M, Ravera A, Filippatos G
    Understanding worsening heart failure as a therapeutic target: another step forward?
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed     Text format    


  335. PASCUAL-FIGAL DA
    Acute heart failure and biomarkers: time also matters, don't relax.
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed     Text format    


  336. VADUGANATHAN M, Patel RB, Butler J, Metra M, et al
    Integrating electronic health records into the study of heart failure: promises and pitfalls.
    Eur J Heart Fail. 2017 May 25. doi: 10.1002.
    PubMed     Text format    


  337. VAN AELST LNL, Abraham M, Sadoune M, Lefebvre T, et al
    Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up.
    Eur J Heart Fail. 2017 May 17. doi: 10.1002.
    PubMed     Text format    


  338. EDELMANN F, Bobenko A, Gelbrich G, Hasenfuss G, et al
    Exercise training in Diastolic Heart Failure (Ex-DHF): rationale and design of a multicentre, prospective, randomized, controlled, parallel group trial.
    Eur J Heart Fail. 2017 May 17. doi: 10.1002.
    PubMed     Text format     Abstract available


  339. MORBACH C, Marx A, Kaspar M, Guder G, et al
    Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides.
    Eur J Heart Fail. 2017 May 17. doi: 10.1002.
    PubMed     Text format     Abstract available


  340. PINTALHAO M, Castro-Chaves P, Bettencourt P
    Are circulating relaxin levels related to pulmonary hypertension in patients with heart failure? A reply.
    Eur J Heart Fail. 2017 May 4. doi: 10.1002.
    PubMed     Text format    


  341. MAMAS MA, Sperrin M, Watson MC, Coutts A, et al
    Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland.
    Eur J Heart Fail. 2017 May 3. doi: 10.1002.
    PubMed     Text format     Abstract available


  342. GREENE SJ, Vaduganathan M, Gheorghiade M
    Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2017 May 2. doi: 10.1002.
    PubMed     Text format    



  343. Abstracts of the Heart Failure 2017 and the 4th World Congress on Acute Heart Failure, Paris, France, 29 April - 2 May 2017.
    Eur J Heart Fail. 2017;19 Suppl 1:5-601.
    PubMed     Text format    


  344. AHMAD T, Testani JM
    What happens to stable heart failure patients when they don't take their medicines?
    Eur J Heart Fail. 2017;19:650-651.
    PubMed     Text format    


  345. NAGELE MP
    Pulmonary artery pressure-based telemedicine in heart failure: ready for Europe?
    Eur J Heart Fail. 2017;19:670-672.
    PubMed     Text format    


  346. LEHLE K, Lubnow M, Philipp A, Foltan M, et al
    Prevalence of hemolysis and metabolic acidosis in patients with circulatory failure supported with extracorporeal life support: a marker for survival?
    Eur J Heart Fail. 2017;19 Suppl 2:110-116.
    PubMed     Text format     Abstract available


  347. ROELEVELD PP
    What is new in pediatric ECMO? 2016, a year in review.
    Eur J Heart Fail. 2017;19 Suppl 2:92-96.
    PubMed     Text format     Abstract available


  348. SOROKIN V, MacLaren G, Vidanapathirana PC, Delnoij T, et al
    Choosing the appropriate configuration and cannulation strategies for extracorporeal membrane oxygenation: the potential dynamic process of organ support and importance of hybrid modes.
    Eur J Heart Fail. 2017;19 Suppl 2:75-83.
    PubMed     Text format     Abstract available


  349. OSTADAL P, Rokyta R, Kruger A, Vondrakova D, et al
    Extra corporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS): rationale and design of the multicenter randomized trial.
    Eur J Heart Fail. 2017;19 Suppl 2:124-127.
    PubMed     Text format     Abstract available


  350. DEN UIL CA, Jewbali LS, Heeren MJ, Constantinescu AA, et al
    Isolated left ventricular failure is a predictor of poor outcome in patients receiving veno-arterial extracorporeal membrane oxygenation.
    Eur J Heart Fail. 2017;19 Suppl 2:104-109.
    PubMed     Text format     Abstract available


    April 2017
  351. KOMAJDA M, Cowie MR, Tavazzi L, Ponikowski P, et al
    Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry.
    Eur J Heart Fail. 2017 Apr 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  352. CHIONCEL O, Mebazaa A, Harjola VP, Coats AJ, et al
    Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2017 Apr 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  353. KOMAJDA M, Isnard R, Cohen-Solal A, Metra M, et al
    Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
    Eur J Heart Fail. 2017 Apr 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  354. TEERLINK JR, Voors AA, Ponikowski P, Pang PS, et al
    Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.
    Eur J Heart Fail. 2017 Apr 28. doi: 10.1002.
    PubMed     Text format     Abstract available


  355. ANKER SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, et al
    Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
    Eur J Heart Fail. 2017 Apr 24. doi: 10.1002.
    PubMed     Text format     Abstract available


  356. VINEREANU D, Margulescu AD
    The fallacy of resting echocardiographic parameters of cardiac function in heart failure with preserved ejection fraction: add global longitudinal strain to the list.
    Eur J Heart Fail. 2017 Apr 19. doi: 10.1002.
    PubMed     Text format    


  357. FERREIRA JP, Mentz RJ, Pizard A, Pitt B, et al
    Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?
    Eur J Heart Fail. 2017 Apr 12. doi: 10.1002.
    PubMed     Text format     Abstract available


  358. HULOT JS, Salem JE, Redheuil A, Collet JP, et al
    Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial.
    Eur J Heart Fail. 2017 Apr 10. doi: 10.1002.
    PubMed     Text format     Abstract available


  359. LUPON J, Diez-Lopez C, de Antonio M, Domingo M, et al
    Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
    Eur J Heart Fail. 2017 Apr 6. doi: 10.1002.
    PubMed     Text format     Abstract available


  360. CHIONCEL O, Lainscak M, Seferovic PM, Anker SD, et al
    Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2017 Apr 6. doi: 10.1002.
    PubMed     Text format     Abstract available


  361. TKACZYSZYN M, Comin-Colet J, Voors AA, van Veldhuisen DJ, et al
    Iron deficiency and red cell indices in patients with heart failure.
    Eur J Heart Fail. 2017 Apr 6. doi: 10.1002.
    PubMed     Text format     Abstract available


  362. VENTURA HO, Messerli FH, Lavie CJ
    Observations on the blood pressure paradox in heart failure.
    Eur J Heart Fail. 2017 Apr 3. doi: 10.1002.
    PubMed     Text format    


  363. LYONS OD, Floras JS, Logan AG, Beanlands R, et al
    Design of the effect of adaptive servo-ventilation on survival and cardiovascular hospital admissions in patients with heart failure and sleep apnoea: the ADVENT-HF trial.
    Eur J Heart Fail. 2017;19:579-587.
    PubMed     Text format     Abstract available


  364. DEFTEREOS S, Giannopoulos G, Panagopoulou V, Filippatos G, et al
    Surrogate endpoints in heart failure: (once again) use with caution.
    Eur J Heart Fail. 2017;19:563-565.
    PubMed     Text format    


  365. PLICHART M, Orvoen G, Jourdain P, Quinquis L, et al
    Brain natriuretic peptide usefulness in very elderly dyspnoeic patients: the BED study.
    Eur J Heart Fail. 2017;19:540-548.
    PubMed     Text format     Abstract available


  366. BRISTOW MR, Sharma K, Assmann SF, Linas S, et al
    Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT.
    Eur J Heart Fail. 2017;19:457-465.
    PubMed     Text format     Abstract available


  367. JANSWEIJER JA, Nieuwhof K, Russo F, Hoorntje ET, et al
    Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy.
    Eur J Heart Fail. 2017;19:512-521.
    PubMed     Text format     Abstract available


  368. ZANNAD F
    Monitoring renal safety in mineralocorticoid receptor antagonist trials.
    Eur J Heart Fail. 2017;19:466-468.
    PubMed     Text format    


  369. BALLIGAND JL
    Cardiac beta3-adrenergic receptors in the clinical arena: the end of the beginning.
    Eur J Heart Fail. 2017;19:576-578.
    PubMed     Text format    


  370. SENNI M, Ferrero P, Iacovoni A
    Prognostic scores: one fits all?
    Eur J Heart Fail. 2017;19:588.
    PubMed     Text format    


  371. VAN LINTHOUT S, Tschope C
    Lost in markers? Time for phenomics and phenomapping in dilated cardiomyopathy.
    Eur J Heart Fail. 2017;19:499-501.
    PubMed     Text format    


    March 2017
  372. ROM O, Aviram M
    High-density lipoprotein-associated paraoxonase 1: a possible prognostic biomarker for heart failure?
    Eur J Heart Fail. 2017 Mar 31. doi: 10.1002.
    PubMed     Text format    


  373. TSUJI K, Sakata Y, Nochioka K, Miura M, et al
    Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study.
    Eur J Heart Fail. 2017 Mar 31. doi: 10.1002.
    PubMed     Text format     Abstract available


  374. LOFMAN I, Szummer K, Dahlstrom U, Jernberg T, et al
    Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.
    Eur J Heart Fail. 2017 Mar 29. doi: 10.1002.
    PubMed     Text format     Abstract available


  375. MONTERO D, Flammer AJ
    Exercise intolerance in heart failure with preserved ejection fraction: time to scrutinize diuretic therapy?
    Eur J Heart Fail. 2017 Mar 29. doi: 10.1002.
    PubMed     Text format    


  376. SCHMID FA, Schlager O, Keller P, Seifert B, et al
    Prognostic value of long-term blood pressure changes in patients with chronic heart failure.
    Eur J Heart Fail. 2017 Mar 27. doi: 10.1002.
    PubMed     Text format     Abstract available


  377. COWIE MR, Filippatos GS, Alonso Garcia ML, Anker SD, et al
    New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment.
    Eur J Heart Fail. 2017 Mar 27. doi: 10.1002.
    PubMed     Text format     Abstract available


  378. DEVAUX Y, Creemers EE, Boon RA, Werfel S, et al
    Circular RNAs in heart failure.
    Eur J Heart Fail. 2017 Mar 27. doi: 10.1002.
    PubMed     Text format     Abstract available


  379. PIEPOLI MF
    Obesity in heart failure: is it time to rethink the paradox?
    Eur J Heart Fail. 2017 Mar 24. doi: 10.1002.
    PubMed     Text format    


  380. D'ELIA E, Iacovoni A, Vaduganathan M, Lorini FL, et al
    Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.
    Eur J Heart Fail. 2017 Mar 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  381. BIERING-SORENSEN T, Shah SJ, Anand I, Sweitzer N, et al
    Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2017 Mar 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  382. MCDONALD K, O'Hanlon R, Savage HO, Khushaba RN, et al
    Sleep-disordered breathing in chronic heart failure is highly variable when measured remotely using a novel non-contact biomotion sensor.
    Eur J Heart Fail. 2017 Mar 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  383. OLIVIER A, Pitt B, Girerd N, Lamiral Z, et al
    Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity: Insight from the EMPHASIS-HF trial.
    Eur J Heart Fail. 2017 Mar 16. doi: 10.1002.
    PubMed     Text format     Abstract available


  384. SHARMA K, Fang JC
    The heart-kidney relationship in heart failure: it's not you, it's me.
    Eur J Heart Fail. 2017 Mar 15. doi: 10.1002.
    PubMed     Text format    


  385. RICKENBACHER P, Kaufmann BA, Maeder MT, Bernheim A, et al
    Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF).
    Eur J Heart Fail. 2017 Mar 15. doi: 10.1002.
    PubMed     Text format     Abstract available


  386. DOVANCESCU S, Pellicori P, Mabote T, Torabi A, et al
    The effects of short-term omission of daily medication on the pathophysiology of heart failure.
    Eur J Heart Fail. 2017 Mar 15. doi: 10.1002.
    PubMed     Text format     Abstract available


  387. CLELAND JG, Teerlink JR, Davison BA, Shoaib A, et al
    Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studie
    Eur J Heart Fail. 2017 Mar 10. doi: 10.1002.
    PubMed     Text format     Abstract available


  388. SLIWA K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, et al
    Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM.
    Eur J Heart Fail. 2017 Mar 8. doi: 10.1002.
    PubMed     Text format     Abstract available



  389. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions.
    Eur J Heart Fail. 2017;19:438.
    PubMed     Text format    


  390. DIERCKX R, Inglis SC, Clark RA, Prieto-Merino D, et al
    Telemedicine in heart failure: new insights from the Cochrane meta-analyses.
    Eur J Heart Fail. 2017;19:304-306.
    PubMed     Text format    


  391. PAN A
    The real-world evidence of heart failure co-morbidities.
    Eur J Heart Fail. 2017;19:434.
    PubMed     Text format    


  392. BRISTOW MR
    Genetic variation expressed in the brain may impact heart failure.
    Eur J Heart Fail. 2017;19:324-325.
    PubMed     Text format    


  393. MCDONALD K, Gallagher J
    The practice gap in heart failure-the elephant in the room.
    Eur J Heart Fail. 2017;19:301-303.
    PubMed     Text format    


  394. MAASS AH, DeJongste MJ, van der Meer P
    Neuromodulation for systolic heart failure: more than a placebo effect?
    Eur J Heart Fail. 2017;19:401-403.
    PubMed     Text format    



  395. Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology.
    Eur J Heart Fail. 2017;19:437.
    PubMed     Text format    


  396. DEMISSEI BG, Postmus D, Cleland JG, O'Connor CM, et al
    Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure.
    Eur J Heart Fail. 2017 Mar 1. doi: 10.1002.
    PubMed     Text format     Abstract available


  397. VOORS AA, Ouwerkerk W, Zannad F, van Veldhuisen DJ, et al
    Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure.
    Eur J Heart Fail. 2017 Mar 1. doi: 10.1002.
    PubMed     Text format     Abstract available


  398. PAPPALARDO F, Schulte C, Pieri M, Schrage B, et al
    Concomitant implantation of Impella(R) on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock.
    Eur J Heart Fail. 2017;19:404-412.
    PubMed     Text format     Abstract available


  399. BORIANI G, Malavasi VL
    Patient outcome after implant of a cardioverter defibrillator in the 'real world': the key role of co-morbidities.
    Eur J Heart Fail. 2017;19:387-390.
    PubMed     Text format    


  400. BEHAR JM, Rajani R, Rinaldi CA
    Guided left ventricular lead placement for cardiac resynchronization therapy: an opportunity for image integration.
    Eur J Heart Fail. 2017;19:435.
    PubMed     Text format    


  401. LORUSSO R
    Are two crutches better than one? The ongoing dilemma on the effects and need for left ventricular unloading during veno-arterial extracorporeal membrane oxygenation.
    Eur J Heart Fail. 2017;19:413-415.
    PubMed     Text format    


    February 2017
  402. EMMENS JE, Ter Maaten JM, Voors AA
    Are circulating relaxin levels related to pulmonary hypertension in patients with heart failure?
    Eur J Heart Fail. 2017 Feb 28. doi: 10.1002.
    PubMed     Text format    


  403. PELLICORI P, Urbinati A, Shah P, MacNamara A, et al
    What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?
    Eur J Heart Fail. 2017 Feb 27. doi: 10.1002.
    PubMed     Text format     Abstract available


  404. PAOLILLO S, Mapelli M, Bonomi A, Corra U, et al
    Prognostic role of beta-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database.
    Eur J Heart Fail. 2017 Feb 24. doi: 10.1002.
    PubMed     Text format     Abstract available


  405. VAN SPALL HG, Rahman T, Mytton O, Ramasundarahettige C, et al
    Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis.
    Eur J Heart Fail. 2017 Feb 24. doi: 10.1002.
    PubMed     Text format     Abstract available


  406. LUND LH, Carrero JJ, Farahmand B, Henriksson KM, et al
    Association between enrolment in a heart failure quality registry and subsequent mortality-a nationwide cohort study.
    Eur J Heart Fail. 2017 Feb 23. doi: 10.1002.
    PubMed     Text format     Abstract available


  407. PARASKEVAIDIS IA, Ikonomidis I, Simitsis P, Parissis J, et al
    Multidimensional contractile reserve predicts adverse outcome in patients with severe systolic heart failure: a 4-year follow-up study.
    Eur J Heart Fail. 2017 Feb 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  408. NAYOR M, Larson MG, Wang N, Santhanakrishnan R, et al
    The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction.
    Eur J Heart Fail. 2017 Feb 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  409. GUSTAFSSON F, Rogers JG
    Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes.
    Eur J Heart Fail. 2017 Feb 15. doi: 10.1002.
    PubMed     Text format     Abstract available


  410. SCALI MC, Cortigiani L, Simionuc A, Gregori D, et al
    Exercise-induced B-lines identify worse functional and prognostic stage in heart failure patients with depressed left ventricular ejection fraction.
    Eur J Heart Fail. 2017 Feb 15. doi: 10.1002.
    PubMed     Text format     Abstract available


  411. EMDIN M, Aimo A, Passino C, Vergaro G, et al
    Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly?
    Eur J Heart Fail. 2017 Feb 15. doi: 10.1002.
    PubMed     Text format    


  412. DEVORE AD, McNulty S, Alenezi F, Ersboll M, et al
    Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial.
    Eur J Heart Fail. 2017 Feb 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  413. HAMMADAH M, Kalogeropoulos AP, Georgiopoulou VV, Weber M, et al
    High-density lipoprotein-associated paraoxonase-1 activity for prediction of adverse outcomes in outpatients with chronic heart failure.
    Eur J Heart Fail. 2017 Feb 7. doi: 10.1002.
    PubMed     Text format     Abstract available


  414. COWIE MR, Simon M, Klein L, Thokala P, et al
    The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective.
    Eur J Heart Fail. 2017 Feb 7. doi: 10.1002.
    PubMed     Text format     Abstract available


  415. LUND LH, Braunschweig F, Benson L, Stahlberg M, et al
    Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2017 Feb 7. doi: 10.1002.
    PubMed     Text format     Abstract available


  416. HARJOLA P, Tolonen J, Boyd J, Mattila J, et al
    The role of pre-hospital management in acute heart failure.
    Eur J Heart Fail. 2017;19:287-289.
    PubMed     Text format    


  417. STEWART COATS AJ
    Early abnormalities of cerebral blood flow in mild non-ischaemic heart failure: part of a whole-body response?
    Eur J Heart Fail. 2017;19:269-270.
    PubMed     Text format    


  418. NAAR J, Jaye D, Linde C, Neuzil P, et al
    Spinal cord stimulation in heart failure: effect on disease-associated biomarkers.
    Eur J Heart Fail. 2017;19:283-286.
    PubMed     Text format    


  419. METRA M
    February 2017 at a glance: fibrosis, acute heart failure and neurologic abnormalities.
    Eur J Heart Fail. 2017;19:165-166.
    PubMed     Text format    


  420. AHMAD T, Testani JM
    Haemoconcentration as a treatment goal in heart failure: ready for prime time?
    Eur J Heart Fail. 2017;19:237-240.
    PubMed     Text format    


  421. GYONGYOSI M, Winkler J, Ramos I, Do QT, et al
    Myocardial fibrosis: biomedical research from bench to bedside.
    Eur J Heart Fail. 2017;19:177-191.
    PubMed     Text format     Abstract available


  422. PUYMIRAT E, Fagon JY, Aegerter P, Diehl JL, et al
    Cardiogenic shock in intensive care units: evolution of prevalence, patient profile, management and outcomes, 1997-2012.
    Eur J Heart Fail. 2017;19:192-200.
    PubMed     Text format     Abstract available


    January 2017
  423. DEMISSEI BG, Cotter G, Prescott MF, Felker GM, et al
    A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.
    Eur J Heart Fail. 2017 Jan 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  424. SOKOLSKI M, Zymlinski R, Biegus J, Siwolowski P, et al
    Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure.
    Eur J Heart Fail. 2017 Jan 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  425. PAPADAKI A, Martinez-Gonzalez MA, Alonso-Gomez A, Rekondo J, et al
    Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial.
    Eur J Heart Fail. 2017 Jan 30. doi: 10.1002.
    PubMed     Text format     Abstract available


  426. GUAZZI M
    Is sildenafil neutral on cardiopulmonary performance in group 2 pulmonary hypertension? More details for interpretation.
    Eur J Heart Fail. 2017 Jan 30. doi: 10.1002.
    PubMed     Text format    


  427. GRUSON D, Pouleur AC, Makris K, Chrysohoou C, et al
    Systematic vitamin D supplementation and monitoring: improving outcomes in heart failure?
    Eur J Heart Fail. 2017 Jan 24. doi: 10.1002.
    PubMed     Text format    


  428. DE KEULENAER GW, Segers VF, Zannad F, Brutsaert DL, et al
    The future of pleiotropic therapy in heart failure. Lessons from the benefits of exercise training on endothelial function.
    Eur J Heart Fail. 2017 Jan 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  429. TER MAATEN JM, Rao VS, Hanberg JS, Perry Wilson F, et al
    Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure.
    Eur J Heart Fail. 2017 Jan 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  430. GUAZZI M, van Heerebeek L, Paulus WJ
    Phosphodiesterase-5 inhibition in heart failure with preserved ejection fraction: trading therapy for prevention.
    Eur J Heart Fail. 2017 Jan 19. doi: 10.1002.
    PubMed     Text format    


  431. KOMAJDA M
    Liraglutide in heart failure: caution is needed.
    Eur J Heart Fail. 2017;19:78-79.
    PubMed     Text format    


  432. EZEKOWITZ JA, Armstrong PW
    Diabetes and heart failure in the crosshairs: where is the target?
    Eur J Heart Fail. 2017;19:66-68.
    PubMed     Text format    


  433. GWIZDALA A, Rozwadowska N, Kolanowski TJ, Malcher A, et al
    Safety, feasibility and effectiveness of first in-human administration of muscle-derived stem/progenitor cells modified with connexin-43 gene for treatment of advanced chronic heart failure.
    Eur J Heart Fail. 2017;19:148-157.
    PubMed     Text format     Abstract available


  434. BIERING-SORENSEN T, Santos M, Rivero J, McCullough SD, et al
    Left ventricular deformation at rest predicts exercise-induced elevation in pulmonary artery wedge pressure in patients with unexplained dyspnoea.
    Eur J Heart Fail. 2017;19:101-110.
    PubMed     Text format     Abstract available


  435. NAGELE MP, Steffel J, Robertson M, Singh JP, et al
    Effect of cardiac resynchronization therapy in patients with diabetes randomized in EchoCRT.
    Eur J Heart Fail. 2017;19:80-87.
    PubMed     Text format     Abstract available


  436. TAMPAKAKIS E, Tedford RJ
    Balancing the positives and negatives of the diastolic pulmonary gradient.
    Eur J Heart Fail. 2017;19:98-100.
    PubMed     Text format    


  437. EL-BATTRAWY I, Borggrefe M, Akin I
    Predictors of mortality in Takotsubo cardiomyopathy.
    Eur J Heart Fail. 2017;19:158.
    PubMed     Text format    


    December 2016
  438. KOUDSTAAL S, Pujades-Rodriguez M, Denaxas S, Gho JM, et al
    Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people.
    Eur J Heart Fail. 2016 Dec 23. doi: 10.1002.
    PubMed     Text format     Abstract available


  439. FARMAKIS D, Triposkiadis F, Lekakis J, Parissis J, et al
    Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, and management.
    Eur J Heart Fail. 2016 Dec 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  440. MATYAS C, Nemeth BT, Olah A, Torok M, et al
    Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.
    Eur J Heart Fail. 2016 Dec 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  441. ANGERMANN CE, Kaspar M, Marx A, Kittel-Schneider S, et al
    A functional variant of the neuropeptide S receptor-1 gene modulates clinical outcomes and healthcare utilization in patients with systolic heart failure: results from the Interdisciplinary Network Heart Failure (INH) Study.
    Eur J Heart Fail. 2016 Dec 18. doi: 10.1002.
    PubMed     Text format     Abstract available


  442. BUNDGAARD H, Axelsson A, Hartvig Thomsen J, Sorgaard M, et al
    The-first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial.
    Eur J Heart Fail. 2016 Dec 18. doi: 10.1002.
    PubMed     Text format     Abstract available


  443. SABBAH HN
    Silent disease progression in clinically stable heart failure.
    Eur J Heart Fail. 2016 Dec 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  444. SILVESTRE OM, Goncalves A, Nadruz W Jr, Claggett B, et al
    Ferritin levels and risk of heart failure-the Atherosclerosis Risk in Communities Study.
    Eur J Heart Fail. 2016 Dec 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  445. CLELAND JG
    Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably!
    Eur J Heart Fail. 2016 Dec 11. doi: 10.1002.
    PubMed     Text format    


  446. BOHM M
    Heart rate: from heart failure to chronic diseases and cancer. Is there a role for supportive care by heart rate reduction?
    Eur J Heart Fail. 2016 Dec 4. doi: 10.1002.
    PubMed     Text format    


  447. VON HAEHLING S, Papp Z, Anker SD
    ESC Heart Failure: a new journal aims to broaden heart failure views.
    Eur J Heart Fail. 2016;18:1415-1419.
    PubMed     Text format    


    November 2016
  448. DUCA F, Zotter-Tufaro C, Kammerlander AA, Panzenbock A, et al
    Cardiac extracellular matrix is associated with adverse outcome in patients with chronic heart failure.
    Eur J Heart Fail. 2016 Nov 27. doi: 10.1002.
    PubMed     Text format     Abstract available


  449. REDDY YN, Borlaug BA
    Sildenafil, unbridled optimism, and heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2016 Nov 21. doi: 10.1002.
    PubMed     Text format    


  450. LIU LC, Hummel YM, van der Meer P, Berger RM, et al
    Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension.
    Eur J Heart Fail. 2016 Nov 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  451. ROSSIGNOL P, Girerd N, Bakris G, Vardeny O, et al
    Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia.
    Eur J Heart Fail. 2016 Nov 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  452. CANNON JA, Shen L, Jhund PS, Kristensen SL, et al
    Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2016 Nov 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  453. GORTER TM, Rienstra M, van Veldhuisen DJ
    Right ventricular dysfunction in heart failure with reduced vs. preserved ejection fraction: non-identical twins?
    Eur J Heart Fail. 2016 Nov 17. doi: 10.1002.
    PubMed     Text format    


  454. GHIO S, Guazzi M, Scardovi AB, Klersy C, et al
    Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction.
    Eur J Heart Fail. 2016 Nov 17. doi: 10.1002.
    PubMed     Text format     Abstract available


  455. ERKELENS CD, van der Wal HH, de Jong BM, Elting JW, et al
    Dynamics of cerebral blood flow in patients with mild non-ischaemic heart failure.
    Eur J Heart Fail. 2016 Nov 14. doi: 10.1002.
    PubMed     Text format     Abstract available


  456. PACKER M, Holcomb R, Abraham WT, Anker S, et al
    Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure.
    Eur J Heart Fail. 2016 Nov 13. doi: 10.1002.
    PubMed     Text format     Abstract available


  457. HEGGERMONT WA, Papageorgiou AP, Heymans S, van Bilsen M, et al
    Metabolic support for the heart: complementary therapy for heart failure?
    Eur J Heart Fail. 2016 Nov 4. doi: 10.1002.
    PubMed     Text format     Abstract available


  458. PARISSIS J, Nikolaou M, Mebazaa A
    The Model for End-stage Liver Disease score in acute heart failure: hepatorenal dysfunction hides behind.
    Eur J Heart Fail. 2016 Nov 4. doi: 10.1002.
    PubMed     Text format    


  459. KAJIMOTO K, Takano T
    Role of functional mitral regurgitation in heart failure with preserved ejection fraction: an unrecognized protagonist?: reply.
    Eur J Heart Fail. 2016 Nov 4. doi: 10.1002.
    PubMed     Text format    


  460. TRIPOSKIADIS F, Pieske B, Butler J, Parissis J, et al
    Global left atrial failure in heart failure.
    Eur J Heart Fail. 2016;18:1307-1320.
    PubMed     Text format     Abstract available


  461. JHUND PS
    Geographic variation in heart failure-a matter of celebration or condemnation?
    Eur J Heart Fail. 2016;18:1329-1330.
    PubMed     Text format    


  462. METRA M
    November 2016 at a glance: the left atrium, screening for heart failure, multimodality imaging for cardiac resynchronization therapy.
    Eur J Heart Fail. 2016;18:1305-1306.
    PubMed     Text format    


  463. MEIJERS WC, de Boer RA, Ho JE
    Biomarkers to identify and prevent new-onset heart failure in the community.
    Eur J Heart Fail. 2016;18:1351-1352.
    PubMed     Text format    


  464. YANG H, Negishi K, Wang Y, Nolan M, et al
    Echocardiographic screening for non-ischaemic stage B heart failure in the community.
    Eur J Heart Fail. 2016;18:1331-1339.
    PubMed     Text format     Abstract available


  465. HAUGAA KH, Edvardsen T
    Global longitudinal strain: the best biomarker for predicting prognosis in heart failure?
    Eur J Heart Fail. 2016;18:1340-1341.
    PubMed     Text format    


    October 2016
  466. ARRIGO M, Gayat E, Parenica J, Ishihara S, et al
    Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry.
    Eur J Heart Fail. 2016 Oct 28. doi: 10.1002.
    PubMed     Text format     Abstract available


  467. TARGHER G, Dauriz M, Laroche C, Temporelli PL, et al
    In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry.
    Eur J Heart Fail. 2016 Oct 28. doi: 10.1002.
    PubMed     Text format     Abstract available


  468. JORSAL A, Kistorp C, Holmager P, Tougaard RS, et al
    Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
    Eur J Heart Fail. 2016 Oct 28. doi: 10.1002.
    PubMed     Text format     Abstract available


  469. COIRO S, Girerd N, Rossignol P, Ferreira JP, et al
    Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myoc
    Eur J Heart Fail. 2016 Oct 24. doi: 10.1002.
    PubMed     Text format     Abstract available


  470. DIEZ J
    Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.
    Eur J Heart Fail. 2016 Oct 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  471. MEIJERS WC, van der Velde AR, Muller Kobold AC, Dijck-Brouwer J, et al
    Variability of biomarkers in patients with chronic heart failure and healthy controls.
    Eur J Heart Fail. 2016 Oct 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  472. KLIP IT, Voors AA, Swinkels DW, Bakker SJ, et al
    Serum ferritin and risk for new-onset heart failure and cardiovascular events in the community.
    Eur J Heart Fail. 2016 Oct 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  473. BREIDTHARDT T, Weidmann ZM, Twerenbold R, Gantenbein C, et al
    Impact of haemoconcentration during acute heart failure therapy on mortality and its relationship with worsening renal function.
    Eur J Heart Fail. 2016 Oct 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  474. GREENE SJ, Fonarow GC, Solomon SD, Subacius HP, et al
    Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial.
    Eur J Heart Fail. 2016 Oct 17. doi: 10.1002.
    PubMed     Text format     Abstract available


  475. NAGY AI, Venkateshvaran A, Merkely B, Lund LH, et al
    Determinants and prognostic implications of the negative diastolic pulmonary pressure gradient in patients with pulmonary hypertension due to left heart disease.
    Eur J Heart Fail. 2016 Oct 17. doi: 10.1002.
    PubMed     Text format     Abstract available


  476. OBOKATA M, Borlaug BA
    Right ventricular dysfunction and pulmonary hypertension in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2016 Oct 13. doi: 10.1002.
    PubMed     Text format    


  477. BIEGUS J, Zymlinski R, Sokolski M, Siwolowski P, et al
    Impaired hepato-renal function defined by the MELD XI score as prognosticator in acute heart failure.
    Eur J Heart Fail. 2016 Oct 6. doi: 10.1002.
    PubMed     Text format     Abstract available


  478. METRA M
    October 2016 at a glance: treatment of heart failure.
    Eur J Heart Fail. 2016;18:1209-1210.
    PubMed     Text format    


  479. VADUGANATHAN M, Patel RB, Yancy CW
    Stroke prevention in heart failure and sinus rhythm: where do we go from here?
    Eur J Heart Fail. 2016;18:1267-1269.
    PubMed     Text format    


  480. CHAGGAR PS, Williams SG, Yonan N, Fildes J, et al
    Myocardial recovery with mechanical circulatory support.
    Eur J Heart Fail. 2016;18:1220-1227.
    PubMed     Text format     Abstract available


  481. REGOLI F, Bongiorni MG, Rordorf R, Santamaria M, et al
    High recurrence of device-related adverse events following transvenous lead extraction procedure in patients with cardiac resynchronization devices.
    Eur J Heart Fail. 2016;18:1270-1277.
    PubMed     Text format     Abstract available


    September 2016
  482. FITCHETT DH, Udell JA, Inzucchi SE
    Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.
    Eur J Heart Fail. 2016 Sep 21. doi: 10.1002.
    PubMed     Text format     Abstract available


  483. GORTER TM, Hoendermis ES, van Veldhuisen DJ, Voors AA, et al
    Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    Eur J Heart Fail. 2016 Sep 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  484. NIEWINSKI P, Janczak D, Rucinski A, Tubek S, et al
    Carotid body resection for sympathetic modulation in systolic heart failure: results from first-in-man study.
    Eur J Heart Fail. 2016 Sep 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  485. DINI FL, Carluccio E, Simioniuc A, Biagioli P, et al
    Right ventricular recovery during follow-up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction.
    Eur J Heart Fail. 2016 Sep 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  486. ADAMO L, Nassif ME, Novak E, LaRue SJ, et al
    Prevalence of lactic acidaemia in patients with advanced heart failure and depressed cardiac output.
    Eur J Heart Fail. 2016 Sep 20. doi: 10.1002.
    PubMed     Text format     Abstract available


  487. MARTINSON M, Bharmi R, Dalal N, Abraham WT, et al
    Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial.
    Eur J Heart Fail. 2016 Sep 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  488. MELENOVSKY V, Petrak J, Mracek T, Benes J, et al
    Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis.
    Eur J Heart Fail. 2016 Sep 19. doi: 10.1002.
    PubMed     Text format     Abstract available


  489. SANTAS E, Nunez E, Nunez J
    Role of functional mitral regurgitation in heart failure with preserved ejection fraction: an unrecognized protagonist?
    Eur J Heart Fail. 2016 Sep 19. doi: 10.1002.
    PubMed     Text format    


  490. ADAMSON PB, Ginn G, Anker SD, Bourge RC, et al
    Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trials.
    Eur J Heart Fail. 2016 Sep 16. doi: 10.1002.
    PubMed     Text format     Abstract available


  491. KITAI T, Grodin JL, Mentz RJ, Hernandez AF, et al
    Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial.
    Eur J Heart Fail. 2016 Sep 16. doi: 10.1002.
    PubMed     Text format     Abstract available


  492. IBRAHIM I, Kuan WS, Frampton C, Troughton R, et al
    Superior performance of N-terminal pro brain natriuretic peptide for diagnosis of acute decompensated heart failure in an Asian compared with a Western setting.
    Eur J Heart Fail. 2016 Sep 13. doi: 10.1002.
    PubMed     Text format     Abstract available


  493. ADELBORG K, Horvath-Puho E, Ording A, Pedersen L, et al
    Heart failure and risk of dementia: a Danish nationwide population-based cohort study.
    Eur J Heart Fail. 2016 Sep 9. doi: 10.1002.
    PubMed     Text format     Abstract available


  494. OMERSA D, Farkas J, Erzen I, Lainscak M, et al
    National trends in heart failure hospitalization rates in Slovenia 2004-2012.
    Eur J Heart Fail. 2016 Sep 9. doi: 10.1002.
    PubMed     Text format     Abstract available


  495. KONSTANTINIDES SV
    Trends in pregnancy outcomes in patients with pulmonary hypertension: still a long way to go.
    Eur J Heart Fail. 2016;18:1129-31.
    PubMed     Text format    


    July 2016
  496. SLIWA K, van Hagen IM, Budts W, Swan L, et al
    Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology.
    Eur J Heart Fail. 2016 Jul 7. doi: 10.1002.
    PubMed     Text format     Abstract available


    February 2016
  497. METRA M
    February 2016 at a glance. Focus issue on cardiac regeneration, medical treatment and cardiac devices.
    Eur J Heart Fail. 2016;18:127.
    PubMed     Text format    


  498. VADUGANATHAN M, Prasad V
    Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?
    Eur J Heart Fail. 2016;18:128-32.
    PubMed     Text format    


  499. STOLFO D, Tonet E, Merlo M, Barbati G, et al
    Early right ventricular response to cardiac resynchronization therapy: impact on clinical outcomes.
    Eur J Heart Fail. 2016;18:205-13.
    PubMed     Text format     Abstract available


  500. BATTY JA, Lima JA Jr, Kunadian V
    Direct cellular reprogramming for cardiac repair and regeneration.
    Eur J Heart Fail. 2016;18:145-56.
    PubMed     Text format     Abstract available


  501. SCHUSSLER-LENZ M, Beuneu C, Menezes-Ferreira M, Jekerle V, et al
    Cell-based therapies for cardiac repair: a meeting report on scientific observations and European regulatory viewpoints.
    Eur J Heart Fail. 2016;18:133-41.
    PubMed     Text format     Abstract available


  502. VADUGANATHAN M, Goldsmith SR, Senni M, Butler J, et al
    Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.
    Eur J Heart Fail. 2016;18:185-91.
    PubMed     Text format     Abstract available


    January 2016
  503. BRAMLAGE P, Swift SL, Thoenes M, Minguet J, et al
    Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.
    Eur J Heart Fail. 2016;18:28-37.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: